WO2010065117A1 - Inhibition of hdac2 to promote memory - Google Patents
Inhibition of hdac2 to promote memory Download PDFInfo
- Publication number
- WO2010065117A1 WO2010065117A1 PCT/US2009/006355 US2009006355W WO2010065117A1 WO 2010065117 A1 WO2010065117 A1 WO 2010065117A1 US 2009006355 W US2009006355 W US 2009006355W WO 2010065117 A1 WO2010065117 A1 WO 2010065117A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hdac2
- inhibitor
- memory
- formula
- mice
- Prior art date
Links
- 230000015654 memory Effects 0.000 title claims abstract description 109
- 230000005764 inhibitory process Effects 0.000 title description 14
- 102100039999 Histone deacetylase 2 Human genes 0.000 claims abstract description 160
- 101001035011 Homo sapiens Histone deacetylase 2 Proteins 0.000 claims abstract description 160
- 238000000034 method Methods 0.000 claims abstract description 111
- 230000002708 enhancing effect Effects 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims description 114
- 239000003112 inhibitor Substances 0.000 claims description 110
- 108090000353 Histone deacetylase Proteins 0.000 claims description 108
- 239000000203 mixture Substances 0.000 claims description 87
- -1 Q-βalkylene Chemical group 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 39
- 125000001072 heteroaryl group Chemical group 0.000 claims description 39
- 125000003118 aryl group Chemical group 0.000 claims description 38
- 238000011282 treatment Methods 0.000 claims description 38
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 36
- 208000024827 Alzheimer disease Diseases 0.000 claims description 34
- 238000009472 formulation Methods 0.000 claims description 34
- 125000002015 acyclic group Chemical group 0.000 claims description 26
- 230000007787 long-term memory Effects 0.000 claims description 26
- 208000000044 Amnesia Diseases 0.000 claims description 24
- 108091034117 Oligonucleotide Proteins 0.000 claims description 24
- 208000026139 Memory disease Diseases 0.000 claims description 22
- 229940124597 therapeutic agent Drugs 0.000 claims description 22
- 230000006984 memory degeneration Effects 0.000 claims description 21
- 208000023060 memory loss Diseases 0.000 claims description 21
- 125000004122 cyclic group Chemical group 0.000 claims description 20
- 239000004055 small Interfering RNA Substances 0.000 claims description 20
- 102100039996 Histone deacetylase 1 Human genes 0.000 claims description 19
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 claims description 19
- 206010012289 Dementia Diseases 0.000 claims description 18
- 108020004459 Small interfering RNA Proteins 0.000 claims description 18
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 102100021455 Histone deacetylase 3 Human genes 0.000 claims description 16
- 101000899282 Homo sapiens Histone deacetylase 3 Proteins 0.000 claims description 16
- 102100022537 Histone deacetylase 6 Human genes 0.000 claims description 15
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 claims description 15
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 claims description 15
- 230000009368 gene silencing by RNA Effects 0.000 claims description 15
- 230000004770 neurodegeneration Effects 0.000 claims description 15
- 208000010877 cognitive disease Diseases 0.000 claims description 14
- 201000004810 Vascular dementia Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 10
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 9
- 102000053642 Catalytic RNA Human genes 0.000 claims description 9
- 108090000994 Catalytic RNA Proteins 0.000 claims description 9
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 230000006378 damage Effects 0.000 claims description 9
- 230000001771 impaired effect Effects 0.000 claims description 9
- 108091092562 ribozyme Proteins 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 9
- 230000000946 synaptic effect Effects 0.000 claims description 9
- 230000008499 blood brain barrier function Effects 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 8
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 8
- 230000007067 DNA methylation Effects 0.000 claims description 7
- 102100021453 Histone deacetylase 5 Human genes 0.000 claims description 7
- 102100038720 Histone deacetylase 9 Human genes 0.000 claims description 7
- 101000899255 Homo sapiens Histone deacetylase 5 Proteins 0.000 claims description 7
- 101001035694 Homo sapiens Polyamine deacetylase HDAC10 Proteins 0.000 claims description 7
- 102100039388 Polyamine deacetylase HDAC10 Human genes 0.000 claims description 7
- 208000027418 Wounds and injury Diseases 0.000 claims description 7
- 230000006735 deficit Effects 0.000 claims description 7
- 238000012544 monitoring process Methods 0.000 claims description 7
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 6
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 6
- 230000003292 diminished effect Effects 0.000 claims description 6
- 125000005549 heteroarylene group Chemical group 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 206010027175 memory impairment Diseases 0.000 claims description 6
- 239000002679 microRNA Substances 0.000 claims description 6
- 101001032113 Homo sapiens Histone deacetylase 7 Proteins 0.000 claims description 5
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 5
- 210000005013 brain tissue Anatomy 0.000 claims description 5
- 125000003107 substituted aryl group Chemical group 0.000 claims description 5
- 229960001685 tacrine Drugs 0.000 claims description 5
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims description 5
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 230000003920 cognitive function Effects 0.000 claims description 4
- 230000001054 cortical effect Effects 0.000 claims description 4
- 230000003412 degenerative effect Effects 0.000 claims description 4
- 230000000638 stimulation Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims description 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical group O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 3
- STRZQWQNZQMHQR-UAKXSSHOSA-N 5-fluorocytidine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 STRZQWQNZQMHQR-UAKXSSHOSA-N 0.000 claims description 3
- LJIRBXZDQGQUOO-KVTDHHQDSA-N 6-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,4-dihydro-1,3,5-triazin-2-one Chemical compound C1NC(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LJIRBXZDQGQUOO-KVTDHHQDSA-N 0.000 claims description 3
- LAOLDMMWVYDDID-KVQBGUIXSA-N 6-amino-3-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,4-dihydro-1,3,5-triazin-2-one Chemical compound C1NC(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 LAOLDMMWVYDDID-KVQBGUIXSA-N 0.000 claims description 3
- 206010036631 Presenile dementia Diseases 0.000 claims description 3
- 206010039966 Senile dementia Diseases 0.000 claims description 3
- 229960002756 azacitidine Drugs 0.000 claims description 3
- 230000007850 degeneration Effects 0.000 claims description 3
- 229960003530 donepezil Drugs 0.000 claims description 3
- 229960003980 galantamine Drugs 0.000 claims description 3
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 3
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 claims description 3
- 229960000244 procainamide Drugs 0.000 claims description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 3
- 229960004136 rivastigmine Drugs 0.000 claims description 3
- RPQZTTQVRYEKCR-WCTZXXKLSA-N zebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=CC=C1 RPQZTTQVRYEKCR-WCTZXXKLSA-N 0.000 claims description 3
- IDYKCXHJJGMAEV-RRKCRQDMSA-N 4-amino-5-fluoro-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 IDYKCXHJJGMAEV-RRKCRQDMSA-N 0.000 claims description 2
- 229940039856 aricept Drugs 0.000 claims description 2
- 230000003727 cerebral blood flow Effects 0.000 claims description 2
- 229940108366 exelon Drugs 0.000 claims description 2
- 230000003340 mental effect Effects 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 108091030071 RNAI Proteins 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 13
- 238000011084 recovery Methods 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 135
- 102000003964 Histone deacetylase Human genes 0.000 description 107
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 97
- 210000004556 brain Anatomy 0.000 description 66
- 230000000694 effects Effects 0.000 description 55
- 210000004027 cell Anatomy 0.000 description 54
- 239000000047 product Substances 0.000 description 53
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical group ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 52
- 238000006640 acetylation reaction Methods 0.000 description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- 230000021736 acetylation Effects 0.000 description 49
- 229960000237 vorinostat Drugs 0.000 description 49
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- 230000001965 increasing effect Effects 0.000 description 48
- 230000001225 therapeutic effect Effects 0.000 description 44
- 230000014509 gene expression Effects 0.000 description 42
- 239000000243 solution Substances 0.000 description 42
- 238000012360 testing method Methods 0.000 description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 38
- 108090000623 proteins and genes Proteins 0.000 description 37
- 235000019439 ethyl acetate Nutrition 0.000 description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 34
- 238000006243 chemical reaction Methods 0.000 description 32
- 239000007787 solid Substances 0.000 description 32
- 230000013016 learning Effects 0.000 description 31
- 239000011780 sodium chloride Substances 0.000 description 30
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 29
- 108010033040 Histones Proteins 0.000 description 27
- 150000007523 nucleic acids Chemical class 0.000 description 27
- 210000002569 neuron Anatomy 0.000 description 26
- 102000039446 nucleic acids Human genes 0.000 description 26
- 108020004707 nucleic acids Proteins 0.000 description 26
- 239000002773 nucleotide Substances 0.000 description 24
- 125000003729 nucleotide group Chemical group 0.000 description 24
- 239000012044 organic layer Substances 0.000 description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
- 230000003750 conditioning effect Effects 0.000 description 22
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 21
- 229910052938 sodium sulfate Inorganic materials 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 20
- 239000000741 silica gel Substances 0.000 description 20
- 229910002027 silica gel Inorganic materials 0.000 description 20
- 235000011152 sodium sulphate Nutrition 0.000 description 20
- 238000012549 training Methods 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 19
- 239000000872 buffer Substances 0.000 description 19
- 239000002904 solvent Substances 0.000 description 19
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 18
- 229940124639 Selective inhibitor Drugs 0.000 description 18
- 230000006399 behavior Effects 0.000 description 18
- 238000004440 column chromatography Methods 0.000 description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 238000002347 injection Methods 0.000 description 17
- 239000007864 aqueous solution Substances 0.000 description 16
- 230000002354 daily effect Effects 0.000 description 16
- 230000008014 freezing Effects 0.000 description 16
- 238000007710 freezing Methods 0.000 description 16
- 210000001320 hippocampus Anatomy 0.000 description 16
- 239000000843 powder Substances 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- 125000000217 alkyl group Chemical group 0.000 description 15
- 239000000074 antisense oligonucleotide Substances 0.000 description 15
- 238000012230 antisense oligonucleotides Methods 0.000 description 15
- 230000001419 dependent effect Effects 0.000 description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 15
- 238000001262 western blot Methods 0.000 description 15
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 14
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 14
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
- 230000027928 long-term synaptic potentiation Effects 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 229920002472 Starch Polymers 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 230000000692 anti-sense effect Effects 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 125000001544 thienyl group Chemical group 0.000 description 11
- 230000001684 chronic effect Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000006195 histone acetylation Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 230000002018 overexpression Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 230000001629 suppression Effects 0.000 description 10
- 210000000225 synapse Anatomy 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 230000008685 targeting Effects 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- 108010010803 Gelatin Proteins 0.000 description 9
- 239000007821 HATU Substances 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 9
- 230000035045 associative learning Effects 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 239000008273 gelatin Substances 0.000 description 9
- 229920000159 gelatin Polymers 0.000 description 9
- 229940014259 gelatin Drugs 0.000 description 9
- 235000019322 gelatine Nutrition 0.000 description 9
- 235000011852 gelatine desserts Nutrition 0.000 description 9
- 238000007912 intraperitoneal administration Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- KXWWYFKVBFUVIZ-SGWCAAJKSA-N n'-hydroxy-n-[(e)-[4-(n-phenylanilino)phenyl]methylideneamino]octanediamide Chemical compound C1=CC(/C=N/NC(=O)CCCCCCC(=O)NO)=CC=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 KXWWYFKVBFUVIZ-SGWCAAJKSA-N 0.000 description 9
- 239000005022 packaging material Substances 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- 108010026424 tau Proteins Proteins 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 102000004243 Tubulin Human genes 0.000 description 8
- 108090000704 Tubulin Proteins 0.000 description 8
- 239000000443 aerosol Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- UMXYJWSQJORGEM-UHFFFAOYSA-N ethene;piperazine Chemical group C=C.C1CNCCN1 UMXYJWSQJORGEM-UHFFFAOYSA-N 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 230000000971 hippocampal effect Effects 0.000 description 8
- 238000011002 quantification Methods 0.000 description 8
- 230000006403 short-term memory Effects 0.000 description 8
- 229940032147 starch Drugs 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000035939 shock Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 108700028369 Alleles Proteins 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 108010077544 Chromatin Proteins 0.000 description 6
- 102400000125 Cyclin-dependent kinase 5 activator 1, p25 Human genes 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical group C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 238000007385 chemical modification Methods 0.000 description 6
- 210000003483 chromatin Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 239000007884 disintegrant Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000003119 immunoblot Methods 0.000 description 6
- 238000012744 immunostaining Methods 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 230000006993 memory improvement Effects 0.000 description 6
- 210000001577 neostriatum Anatomy 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 102000013498 tau Proteins Human genes 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical group C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 102000006947 Histones Human genes 0.000 description 5
- 108700011259 MicroRNAs Proteins 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 239000004005 microsphere Substances 0.000 description 5
- 239000006199 nebulizer Substances 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 150000002894 organic compounds Chemical class 0.000 description 5
- 239000008177 pharmaceutical agent Substances 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 230000004962 physiological condition Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 210000001176 projection neuron Anatomy 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 5
- 210000004129 prosencephalon Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- 230000003956 synaptic plasticity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 4
- 0 *c(cc1)cc(NC(c(cc2)ccc2N(*)I)=O)c1N Chemical compound *c(cc1)cc(NC(c(cc2)ccc2N(*)I)=O)c1N 0.000 description 4
- GOWUDHPKGOIDIX-UHFFFAOYSA-N 2-(4-methyl-1-piperazinyl)ethanamine Chemical compound CN1CCN(CCN)CC1 GOWUDHPKGOIDIX-UHFFFAOYSA-N 0.000 description 4
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical group C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 4
- QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 4
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 108010051219 Cre recombinase Proteins 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 208000028017 Psychotic disease Diseases 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 238000013228 adult male C57BL/6J mice Methods 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 230000001149 cognitive effect Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 4
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000003380 propellant Substances 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 238000007634 remodeling Methods 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 230000007596 spatial working memory Effects 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- NSJVYHOPHZMZPN-UHFFFAOYSA-N (2-methylphenyl)boronic acid Chemical compound CC1=CC=CC=C1B(O)O NSJVYHOPHZMZPN-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100027584 Protein c-Fos Human genes 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 150000005347 biaryls Chemical group 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001713 cholinergic effect Effects 0.000 description 3
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 210000003520 dendritic spine Anatomy 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 230000003291 dopaminomimetic effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000011257 shell material Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000007470 synaptic degeneration Effects 0.000 description 3
- MHSKRLJMQQNJNC-UHFFFAOYSA-N terephthalamide Chemical compound NC(=O)C1=CC=C(C(N)=O)C=C1 MHSKRLJMQQNJNC-UHFFFAOYSA-N 0.000 description 3
- WTRVRWJDMQDBGJ-UHFFFAOYSA-N tert-butyl n-[2-[[4-[2-(4-methylpiperazin-1-yl)ethylcarbamoyl]benzoyl]amino]-4-pyridin-3-ylphenyl]carbamate Chemical compound C1CN(C)CCN1CCNC(=O)C1=CC=C(C(=O)NC=2C(=CC=C(C=2)C=2C=NC=CC=2)NC(=O)OC(C)(C)C)C=C1 WTRVRWJDMQDBGJ-UHFFFAOYSA-N 0.000 description 3
- ARYHTUPFQTUBBG-UHFFFAOYSA-N thiophen-2-ylboronic acid Chemical compound OB(O)C1=CC=CS1 ARYHTUPFQTUBBG-UHFFFAOYSA-N 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 3
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 3
- 238000007492 two-way ANOVA Methods 0.000 description 3
- OOVUYTNTDROHAU-UHFFFAOYSA-N (4-bromo-2-nitrophenyl)carbamic acid Chemical compound OC(=O)NC1=CC=C(Br)C=C1[N+]([O-])=O OOVUYTNTDROHAU-UHFFFAOYSA-N 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- MPMIXABQCGCBTN-UHFFFAOYSA-N 4-[[2-[(2-methylpropan-2-yl)oxycarbonylamino]-5-pyridin-3-ylphenyl]carbamoyl]benzoic acid Chemical compound CC(C)(C)OC(=O)NC1=CC=C(C=2C=NC=CC=2)C=C1NC(=O)C1=CC=C(C(O)=O)C=C1 MPMIXABQCGCBTN-UHFFFAOYSA-N 0.000 description 2
- REIDAMBAPLIATC-UHFFFAOYSA-N 4-methoxycarbonylbenzoic acid Chemical compound COC(=O)C1=CC=C(C(O)=O)C=C1 REIDAMBAPLIATC-UHFFFAOYSA-N 0.000 description 2
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical class OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 2
- 108091027075 5S-rRNA precursor Proteins 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 101150079978 AGRN gene Proteins 0.000 description 2
- 102000003678 AMPA Receptors Human genes 0.000 description 2
- 108090000078 AMPA Receptors Proteins 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 108700019743 Agrin Proteins 0.000 description 2
- 102100040026 Agrin Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 208000024806 Brain atrophy Diseases 0.000 description 2
- 108010040163 CREB-Binding Protein Proteins 0.000 description 2
- 102100021975 CREB-binding protein Human genes 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 2
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 2
- 102000013717 Cyclin-Dependent Kinase 5 Human genes 0.000 description 2
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 2
- 108010051748 Early Growth Response Protein 2 Proteins 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 101150098261 Hdac2 gene Proteins 0.000 description 2
- 102100039869 Histone H2B type F-S Human genes 0.000 description 2
- 102100021454 Histone deacetylase 4 Human genes 0.000 description 2
- 102100038715 Histone deacetylase 8 Human genes 0.000 description 2
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 2
- 101000899259 Homo sapiens Histone deacetylase 4 Proteins 0.000 description 2
- 101001032118 Homo sapiens Histone deacetylase 8 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 238000012347 Morris Water Maze Methods 0.000 description 2
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- KBHCPIJKJQNHPN-UHFFFAOYSA-N N=NP(O)=O Chemical group N=NP(O)=O KBHCPIJKJQNHPN-UHFFFAOYSA-N 0.000 description 2
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- 102000011990 Sirtuin Human genes 0.000 description 2
- 108050002485 Sirtuin Proteins 0.000 description 2
- 102000004874 Synaptophysin Human genes 0.000 description 2
- 108090001076 Synaptophysin Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001299 aldehydes Chemical group 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000007131 anti Alzheimer effect Effects 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 125000005841 biaryl group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- UCAGLBKTLXCODC-UHFFFAOYSA-N carzenide Chemical compound NS(=O)(=O)C1=CC=C(C(O)=O)C=C1 UCAGLBKTLXCODC-UHFFFAOYSA-N 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 235000020186 condensed milk Nutrition 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 150000001923 cyclic compounds Chemical class 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 210000001947 dentate gyrus Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 230000001035 methylating effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical group [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000002213 purine nucleotide Substances 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical group OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 2
- 239000002719 pyrimidine nucleotide Substances 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical class O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 2
- 229960003452 romidepsin Drugs 0.000 description 2
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Chemical class O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 2
- 230000009183 running Effects 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- JNJJINIJWXHEQQ-UHFFFAOYSA-N tert-butyl n-(2-amino-4-thiophen-2-ylphenyl)carbamate Chemical compound C1=C(N)C(NC(=O)OC(C)(C)C)=CC=C1C1=CC=CS1 JNJJINIJWXHEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 2
- 229940029284 trichlorofluoromethane Drugs 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- SDUPQYQRMYZCDN-UHFFFAOYSA-N (2-amino-4-thiophen-2-ylphenyl)carbamic acid Chemical compound C1=C(NC(O)=O)C(N)=CC(C=2SC=CC=2)=C1 SDUPQYQRMYZCDN-UHFFFAOYSA-N 0.000 description 1
- IZUAHLHTQJCCLJ-UHFFFAOYSA-N (2-chloro-1,1,2,2-tetrafluoroethyl) hypochlorite Chemical compound FC(F)(Cl)C(F)(F)OCl IZUAHLHTQJCCLJ-UHFFFAOYSA-N 0.000 description 1
- BQJGHXPJUQZKML-UHFFFAOYSA-N (2-nitro-4-thiophen-2-ylphenyl)carbamic acid Chemical compound C1=C([N+]([O-])=O)C(NC(=O)O)=CC=C1C1=CC=CS1 BQJGHXPJUQZKML-UHFFFAOYSA-N 0.000 description 1
- LLOKIGWPNVSDGJ-AFBVCZJXSA-N (3s,6s,9s,12r)-3,6-dibenzyl-9-[6-[(2s)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone Chemical compound C([C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)CCCCCC(=O)[C@H]1OC1)C1=CC=CC=C1 LLOKIGWPNVSDGJ-AFBVCZJXSA-N 0.000 description 1
- HZWIJOWMGPTNRA-LAYXVCJNSA-N (3s,6s,9s,12r)-3-butan-2-yl-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone Chemical class N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCN2C(=O)[C@H](C(C)CC)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 HZWIJOWMGPTNRA-LAYXVCJNSA-N 0.000 description 1
- SGYJGGKDGBXCNY-QXUYBEEESA-N (3s,9s,12r)-3-benzyl-6,6-dimethyl-9-[6-[(2s)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone Chemical compound C([C@H]1C(=O)NC(C(N[C@@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@@H]2C(=O)N1)=O)(C)C)CCCCC(=O)[C@@H]1CO1 SGYJGGKDGBXCNY-QXUYBEEESA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- QRPSQQUYPMFERG-LFYBBSHMSA-N (e)-5-[3-(benzenesulfonamido)phenyl]-n-hydroxypent-2-en-4-ynamide Chemical class ONC(=O)\C=C\C#CC1=CC=CC(NS(=O)(=O)C=2C=CC=CC=2)=C1 QRPSQQUYPMFERG-LFYBBSHMSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- IQFYYKKMVGJFEH-BIIVOSGPSA-N 2'-deoxythymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-BIIVOSGPSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- OHMHBGPWCHTMQE-UHFFFAOYSA-N 2,2-dichloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)C(Cl)Cl OHMHBGPWCHTMQE-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- IDLHTECVNDEOIY-UHFFFAOYSA-N 2-pyridin-4-ylethanamine Chemical compound NCCC1=CC=NC=C1 IDLHTECVNDEOIY-UHFFFAOYSA-N 0.000 description 1
- XPQIPUZPSLAZDV-UHFFFAOYSA-N 2-pyridylethylamine Chemical compound NCCC1=CC=CC=N1 XPQIPUZPSLAZDV-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- WGMFHSADKZJPGR-UHFFFAOYSA-N 3-(4-acetamidophenyl)prop-2-enoic acid Chemical compound CC(=O)NC1=CC=C(C=CC(O)=O)C=C1 WGMFHSADKZJPGR-UHFFFAOYSA-N 0.000 description 1
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- ZCWBZRBJSPWUPG-UHFFFAOYSA-N 4-bromo-2-nitroaniline Chemical compound NC1=CC=C(Br)C=C1[N+]([O-])=O ZCWBZRBJSPWUPG-UHFFFAOYSA-N 0.000 description 1
- ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- RMIFLIVHJLREFJ-UHFFFAOYSA-N 5-bromo-2-nitroaniline Chemical compound NC1=CC(Br)=CC=C1[N+]([O-])=O RMIFLIVHJLREFJ-UHFFFAOYSA-N 0.000 description 1
- JTDYUFSDZATMKU-UHFFFAOYSA-N 6-(1,3-dioxo-2-benzo[de]isoquinolinyl)-N-hydroxyhexanamide Chemical class C1=CC(C(N(CCCCCC(=O)NO)C2=O)=O)=C3C2=CC=CC3=C1 JTDYUFSDZATMKU-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical class CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 102100033647 Activity-regulated cytoskeleton-associated protein Human genes 0.000 description 1
- 101710177131 Activity-regulated cytoskeleton-associated protein Proteins 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- GWLHFNKLJRZBAI-KGKLHAENSA-N Apicidin C Chemical class N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C(=O)[C@H](C(C)C)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 GWLHFNKLJRZBAI-KGKLHAENSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical class CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- CWXPKZYXRQFNHJ-UHFFFAOYSA-N C1=CC(CNCCNC(=O)C)=CC=C1C=CC(=O)NC1=CC(C=2SC=CC=2)=CC=C1NC(O)=O Chemical compound C1=CC(CNCCNC(=O)C)=CC=C1C=CC(=O)NC1=CC(C=2SC=CC=2)=CC=C1NC(O)=O CWXPKZYXRQFNHJ-UHFFFAOYSA-N 0.000 description 1
- QYNPIIPPAOVCTG-UHFFFAOYSA-N C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC(Br)=CC=C1NC(O)=O Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC(Br)=CC=C1NC(O)=O QYNPIIPPAOVCTG-UHFFFAOYSA-N 0.000 description 1
- IAVYWLFCZKBOMG-UHFFFAOYSA-N C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC(C=2C(=CC=CC=2)C)=CC=C1NC(O)=O Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC(C=2C(=CC=CC=2)C)=CC=C1NC(O)=O IAVYWLFCZKBOMG-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- KEZUHKOOIQKEIT-UHFFFAOYSA-N CC(C)(C)OC(Nc(ccc(-c1ccc[s]1)c1)c1[N+]([O-])=O)=O Chemical compound CC(C)(C)OC(Nc(ccc(-c1ccc[s]1)c1)c1[N+]([O-])=O)=O KEZUHKOOIQKEIT-UHFFFAOYSA-N 0.000 description 1
- VALNWXMPJVPVLQ-UHFFFAOYSA-N CC(C)(C)OC(Nc(ccc(Br)c1)c1[N+]([O-])=O)=O Chemical compound CC(C)(C)OC(Nc(ccc(Br)c1)c1[N+]([O-])=O)=O VALNWXMPJVPVLQ-UHFFFAOYSA-N 0.000 description 1
- NGWVCLZDDUEMBI-UHFFFAOYSA-N CC(C1)C(C(Nc(cc(cc2)-c3cccnc3)c2NC(OC(C)(C)C)=O)=O)=CC=C1C(OC)=O Chemical compound CC(C1)C(C(Nc(cc(cc2)-c3cccnc3)c2NC(OC(C)(C)C)=O)=O)=CC=C1C(OC)=O NGWVCLZDDUEMBI-UHFFFAOYSA-N 0.000 description 1
- WSYPNYSIHRDIIK-DHZHZOJOSA-N CC(NCCNCc1ccc(/C=C/C(Nc2cc(-c3ccc[s]3)ccc2N)=O)cc1)=O Chemical compound CC(NCCNCc1ccc(/C=C/C(Nc2cc(-c3ccc[s]3)ccc2N)=O)cc1)=O WSYPNYSIHRDIIK-DHZHZOJOSA-N 0.000 description 1
- ZVTAIWTYJKFNQK-UHFFFAOYSA-N CC(Nc(cc1)ccc1C(Nc(cc(cc1)-c2c(C)cccc2)c1N)=O)=O Chemical compound CC(Nc(cc1)ccc1C(Nc(cc(cc1)-c2c(C)cccc2)c1N)=O)=O ZVTAIWTYJKFNQK-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- SGYJGGKDGBXCNY-UHFFFAOYSA-N Chlamydocin Natural products N1C(=O)C2CCCN2C(=O)C(CC=2C=CC=CC=2)NC(=O)C(C)(C)NC(=O)C1CCCCCC(=O)C1CO1 SGYJGGKDGBXCNY-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 1
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 102100023580 Cyclic AMP-dependent transcription factor ATF-4 Human genes 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 108091008102 DNA aptamers Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 108091027757 Deoxyribozyme Proteins 0.000 description 1
- DLVJMFOLJOOWFS-UHFFFAOYSA-N Depudecin Chemical class CC(O)C1OC1C=CC1C(C(O)C=C)O1 DLVJMFOLJOOWFS-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 108700019745 Disks Large Homolog 4 Proteins 0.000 description 1
- 102000047174 Disks Large Homolog 4 Human genes 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- 102100023227 E3 SUMO-protein ligase EGR2 Human genes 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102100030652 Glutamate receptor 1 Human genes 0.000 description 1
- 101710087628 Glutamate receptor 1 Proteins 0.000 description 1
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 1
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000905743 Homo sapiens Cyclic AMP-dependent transcription factor ATF-4 Proteins 0.000 description 1
- 101001032092 Homo sapiens Histone deacetylase 9 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 101100506425 Mus musculus Hdac2 gene Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 1
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 1
- PTJGLFIIZFVFJV-UHFFFAOYSA-N N'-hydroxy-N-(3-pyridinyl)octanediamide Chemical class ONC(=O)CCCCCCC(=O)NC1=CC=CN=C1 PTJGLFIIZFVFJV-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-M NAD(1-) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-M 0.000 description 1
- DYWLNNPBTSBVHQ-UHFFFAOYSA-N NC(=O)C1=CC=CC(C=CC(=O)NC=2C(=CC=C(C=2)C=2SC=CC=2)NC(O)=O)=C1 Chemical compound NC(=O)C1=CC=CC(C=CC(=O)NC=2C(=CC=C(C=2)C=2SC=CC=2)NC(O)=O)=C1 DYWLNNPBTSBVHQ-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- MTAQOBOEWINVTG-UHFFFAOYSA-N OC(=O)NC1=CC=C(C=2SC=CC=2)C=C1NC(=O)C(C=C1)=CC=C1C=CC(=O)NCCC1=CC=CC=N1 Chemical compound OC(=O)NC1=CC=C(C=2SC=CC=2)C=C1NC(=O)C(C=C1)=CC=C1C=CC(=O)NCCC1=CC=CC=N1 MTAQOBOEWINVTG-UHFFFAOYSA-N 0.000 description 1
- HUUQIIBPZYFXIN-UHFFFAOYSA-N OC(c(cc1)ccc1C(Nc(cc(cc1)-c2cccnc2)c1I)=O)=O Chemical compound OC(c(cc1)ccc1C(Nc(cc(cc1)-c2cccnc2)c1I)=O)=O HUUQIIBPZYFXIN-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000001300 Perinatal Death Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920001363 Polidocanol Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920000037 Polyproline Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 206010037249 Psychotic behaviour Diseases 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108010038912 Retinoid X Receptors Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- WBTCZXYOKNRFQX-UHFFFAOYSA-N S1(=O)(=O)NC1=O Chemical group S1(=O)(=O)NC1=O WBTCZXYOKNRFQX-UHFFFAOYSA-N 0.000 description 1
- 102100030681 SH3 and multiple ankyrin repeat domains protein 3 Human genes 0.000 description 1
- 101710101741 SH3 and multiple ankyrin repeat domains protein 3 Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102100021994 Synapsin-2 Human genes 0.000 description 1
- 101710197509 Synapsin-2 Proteins 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- GXVXXETYXSPSOA-UHFFFAOYSA-N Trapoxin A Natural products C1OC1C(=O)CCCCCC(C(NC(CC=1C=CC=CC=1)C(=O)N1)=O)NC(=O)C2CCCCN2C(=O)C1CC1=CC=CC=C1 GXVXXETYXSPSOA-UHFFFAOYSA-N 0.000 description 1
- LLOKIGWPNVSDGJ-UHFFFAOYSA-N Trapoxin B Natural products C1OC1C(=O)CCCCCC(C(NC(CC=1C=CC=CC=1)C(=O)N1)=O)NC(=O)C2CCCN2C(=O)C1CC1=CC=CC=C1 LLOKIGWPNVSDGJ-UHFFFAOYSA-N 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 206010063661 Vascular encephalopathy Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- KNXVSJNKTMQKHC-UHFFFAOYSA-N [2-[3-(4-acetamidophenyl)prop-2-enoylamino]-4-ethynylphenyl]carbamic acid Chemical compound C1=CC(NC(=O)C)=CC=C1C=CC(=O)NC1=CC(C#C)=CC=C1NC(O)=O KNXVSJNKTMQKHC-UHFFFAOYSA-N 0.000 description 1
- OYBKJDAFAVVVDI-UHFFFAOYSA-N [2-[3-(4-formylphenyl)prop-2-enoylamino]-4-thiophen-2-ylphenyl]carbamic acid Chemical compound OC(=O)NC1=CC=C(C=2SC=CC=2)C=C1NC(=O)C=CC1=CC=C(C=O)C=C1 OYBKJDAFAVVVDI-UHFFFAOYSA-N 0.000 description 1
- CCUUMCIVKFMNSO-UHFFFAOYSA-N [2-nitro-4-(2-trimethylsilylethynyl)phenyl]carbamic acid Chemical compound C[Si](C)(C)C#CC1=CC=C(NC(O)=O)C([N+]([O-])=O)=C1 CCUUMCIVKFMNSO-UHFFFAOYSA-N 0.000 description 1
- PEJOXQOTUPURDN-UHFFFAOYSA-N [4-(2-methylphenyl)-2-nitrophenyl]carbamic acid Chemical compound CC1=CC=CC=C1C1=CC=C(NC(O)=O)C([N+]([O-])=O)=C1 PEJOXQOTUPURDN-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 230000007000 age related cognitive decline Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 210000002551 anterior cerebral artery Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003831 antifriction material Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 108010082820 apicidin Chemical class 0.000 description 1
- HZWIJOWMGPTNRA-UHFFFAOYSA-N apicidin B Chemical class N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 HZWIJOWMGPTNRA-UHFFFAOYSA-N 0.000 description 1
- GWLHFNKLJRZBAI-UHFFFAOYSA-N apicidin C Chemical class N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCCN2C(=O)C(C(C)C)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 GWLHFNKLJRZBAI-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical group 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 239000002439 beta secretase inhibitor Substances 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910000394 calcium triphosphate Inorganic materials 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- WZNRVWBKYDHTKI-UHFFFAOYSA-N cellulose, acetate 1,2,4-benzenetricarboxylate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.OC(=O)C1=CC(C(=O)O)=CC=C1C(=O)OCC1C(OC2C(C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(COC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)O2)OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)O1 WZNRVWBKYDHTKI-UHFFFAOYSA-N 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 108700023145 chlamydocin Proteins 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000037410 cognitive enhancement Effects 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- DLVJMFOLJOOWFS-INMLLLKOSA-N depudecin Chemical class C[C@@H](O)[C@@H]1O[C@H]1\C=C\[C@H]1[C@H]([C@H](O)C=C)O1 DLVJMFOLJOOWFS-INMLLLKOSA-N 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
- 125000004986 diarylamino group Chemical group 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 101150069842 dlg4 gene Proteins 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 231100001129 embryonic lethality Toxicity 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000036749 excitatory postsynaptic potential Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000003540 gamma secretase inhibitor Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000004326 gyrus cinguli Anatomy 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- GNYCTMYOHGBSBI-UHFFFAOYSA-N helminthsporium carbonum toxin Chemical class N1C(=O)C(C)NC(=O)C(C)NC(=O)C2CCCN2C(=O)C1CCCCCC(=O)C1CO1 GNYCTMYOHGBSBI-UHFFFAOYSA-N 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 108091008634 hepatocyte nuclear factors 4 Proteins 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 108010074724 histone deacetylase 3 Proteins 0.000 description 1
- 230000006197 histone deacetylation Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010569 immunofluorescence imaging Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229950006462 lauromacrogol 400 Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 230000020796 long term synaptic depression Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 230000007595 memory recall Effects 0.000 description 1
- 230000010387 memory retrieval Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- KMFJVYMFCAIRAN-UHFFFAOYSA-N methyl 3-bromobenzoate Chemical compound COC(=O)C1=CC=CC(Br)=C1 KMFJVYMFCAIRAN-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- DAKZISABEDGGSV-UHFFFAOYSA-N n-(2-aminoethyl)acetamide Chemical compound CC(=O)NCCN DAKZISABEDGGSV-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- OYKBQNOPCSXWBL-SNAWJCMRSA-N n-hydroxy-3-[(e)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide Chemical compound ONC(=O)\C=C\C1=CC=CC(C(=O)NO)=C1 OYKBQNOPCSXWBL-SNAWJCMRSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000023837 negative regulation of proteolysis Effects 0.000 description 1
- 230000001423 neocortical effect Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910001120 nichrome Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000044158 nucleic acid binding protein Human genes 0.000 description 1
- 108700020942 nucleic acid binding protein Proteins 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 210000001152 parietal lobe Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- RFWLACFDYFIVMC-UHFFFAOYSA-D pentacalcium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O RFWLACFDYFIVMC-UHFFFAOYSA-D 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- GJSGGHOYGKMUPT-UHFFFAOYSA-N phenoxathiine Chemical compound C1=CC=C2OC3=CC=CC=C3SC2=C1 GJSGGHOYGKMUPT-UHFFFAOYSA-N 0.000 description 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940099511 polysorbate 65 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002469 receptor inverse agonist Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- JZWFDVDETGFGFC-UHFFFAOYSA-N salacetamide Chemical compound CC(=O)NC(=O)C1=CC=CC=C1O JZWFDVDETGFGFC-UHFFFAOYSA-N 0.000 description 1
- 229950009280 salacetamide Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical group [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical group 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 150000008053 sultones Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000003977 synaptic function Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- AGKLVMVJXDFIGC-MDZDMXLPSA-N tert-butyl (e)-3-phenylprop-2-enoate Chemical compound CC(C)(C)OC(=O)\C=C\C1=CC=CC=C1 AGKLVMVJXDFIGC-MDZDMXLPSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- MBUVYNBFRBYDCV-UHFFFAOYSA-N tert-butyl n-[2-[(4-acetamidobenzoyl)amino]-4-(2-phenylethyl)phenyl]carbamate Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC(CCC=2C=CC=CC=2)=CC=C1NC(=O)OC(C)(C)C MBUVYNBFRBYDCV-UHFFFAOYSA-N 0.000 description 1
- NWPMEVNLKYNBLN-ZHACJKMWSA-N tert-butyl n-[2-[(4-acetamidobenzoyl)amino]-4-[(e)-2-phenylethenyl]phenyl]carbamate Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC(\C=C\C=2C=CC=CC=2)=CC=C1NC(=O)OC(C)(C)C NWPMEVNLKYNBLN-ZHACJKMWSA-N 0.000 description 1
- NBQMEBNUJAUUEU-UHFFFAOYSA-N tert-butyl n-[2-[(4-sulfamoylbenzoyl)amino]-4-thiophen-2-ylphenyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(C=2SC=CC=2)C=C1NC(=O)C1=CC=C(S(N)(=O)=O)C=C1 NBQMEBNUJAUUEU-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- GVIJJXMXTUZIOD-UHFFFAOYSA-N thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- GXVXXETYXSPSOA-UFEOFEBPSA-N trapoxin A Chemical compound C([C@H]1C(=O)N2CCCC[C@@H]2C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)CCCCCC(=O)[C@H]1OC1)C1=CC=CC=C1 GXVXXETYXSPSOA-UFEOFEBPSA-N 0.000 description 1
- 108010060597 trapoxin A Proteins 0.000 description 1
- 108010060596 trapoxin B Proteins 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- WTWHYHPOGZUENL-KZKGWZQBSA-N trichostatin B Chemical compound O=C([C@H](C)/C=C(\C)/C=C/C(=O)NO[Fe](ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C=1C=CC(=CC=1)N(C)C)ONC(=O)\C=C\C(\C)=C\[C@@H](C)C(=O)C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 WTWHYHPOGZUENL-KZKGWZQBSA-N 0.000 description 1
- YECWTLGLNDDPGE-PIFXLSLCSA-N trichostatin C Chemical compound C(/[C@@H](C)C(=O)C=1C=CC(=CC=1)N(C)C)=C(/C)\C=C\C(=O)NO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YECWTLGLNDDPGE-PIFXLSLCSA-N 0.000 description 1
- YECWTLGLNDDPGE-UHFFFAOYSA-N trichostatin D Natural products C=1C=C(N(C)C)C=CC=1C(=O)C(C)C=C(C)C=CC(=O)NOC1OC(CO)C(O)C(O)C1O YECWTLGLNDDPGE-UHFFFAOYSA-N 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000014848 ubiquitin-dependent protein catabolic process Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 229940070384 ventolin Drugs 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000007279 water homeostasis Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
Definitions
- 1-3 Only recently have mouse models with extensive neurodegeneration in the forebrain been reported (1-3).
- One of these models is the bi-transgenic CK-p25 Tg mice where expression of p25, a protein implicated in various neurodegenerative diseases (4), is under the control of the CamKII promoter and can be switched on or off with a doxycycline diet (3,5).
- pre-clinical research has not yet explored strategies to recover lost memories after substantial neuronal loss had taken place.
- Neuronal adaptive responses implicated in memory formation and storage, involve functional and structural synaptic changes, which require alterations in gene expression (West, A. E. et al. Proc Natl Acad Sci USA 9S (20), 1 1024-1 1031
- Neurodegenerative diseases of the central nervous system are often associated with impaired learning and memory, eventually leading to dementia.
- An important aspect that has not been addressed extensively in pre-clinical research, is the loss of long- term memories and the exploration of strategies to re-establish access to those memories.
- the current invention provides methods for restoring access to long-term memory after synaptic and neuronal loss has already occurred.
- Environmental enrichment (EE) has been shown to reinstate learning behavior and re-establish access to long-term memories after significant brain atrophy and neuronal loss has already occurred.
- EE also shown herein is a correlation between EE and epigenetic changes. EE increases histone-tail acetylation and changes the level of methylation.
- the invention is a method for enhancing a memory in a subject by administering to the subject an HDAC2 inhibitor in an amount effective to enhance the memory in the subject.
- the HDAC2 inhibitor may be a selective HDAC2 inhibitor.
- the HDAC2 inhibitor is non-selective but is not an HDACl, HDAC5, HDAC6, HDAC7 and/or HDAClO inhibitor.
- the HDAC2 inhibitor is an HDAC1/HDAC2 selective inhibitor or an HDAC1/HDAC2/HDAC3 selective inhibitor.
- the invention provides a method for accessing long-term memory in a subject having diminished access to a long-term memory comprising increasing histone acetylation in an amount effective to reestablish access to long-term memory in the subject.
- the long-term memory is impaired.
- the impairment may be age-related or injury-related.
- a synaptic network in the subject is re-established.
- re-establishing the synaptic network comprises an increase in the number of active brain synapses.
- re-establishing the synaptic network comprises a reversal of neuronal loss.
- the subject has a disorder selected from the group consisting of MCI (mild cognitive impairment), Alzheimer's Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, vascular dementia, progressive supranuclear palsy or cortical basal degeneration.
- MCI mimetic cognitive impairment
- Alzheimer's Disease memory loss
- attention deficit symptoms associated with Alzheimer disease neurodegeneration associated with Alzheimer disease
- dementia of mixed vascular origin dementia of degenerative origin
- pre-senile dementia senile dementia
- dementia associated with Parkinson's disease vascular dementia
- progressive supranuclear palsy or cortical basal degeneration progressive supranuclear palsy or cortical basal degeneration.
- a HDAC3 inhibitor is administered.
- a HDACl 1 inhibitor is administered.
- a DNA methylation inhibitor such as 5-azacytidine, 5-aza-2'deoxycytidine, 5, 6-dihydro-5- azacytidine, 5, 6-dihydro-5-aza-2'deoxycytidine, 5-fluorocytidine, 5-fluoro-
- 2'deoxycytidine, and short oligonucleotides containing 5-aza-2'deoxycytosine, 5, 6- dihydro-5-aza-2'deoxycytosine, and 5-fluoro-2'deoxycytosine, and procainamide, Zebularine, and (-)-egallocatechin-3-gallate is administered.
- An additional therapeutic agent such as ARICEPT or donepezil, COGNEX or tacrine, EXELON or rivastigmine, REMINYL or galantamine, anti-amyloid vaccine, Abeta-lowering therapies, mental exercise or stimulation may be administered.
- the HDAC2 inhibitor is an HDAC2 RNAi such as a siRNA, shRNA, miRNA, dsRNA or ribozyme or variants thereof.
- the HDAC2 inhibitor may be administered orally, intravenously, cutaneously, subcutaneously, nasally, imtramuscularly, intraperitoneal Iy, intracranially, or intracerebroventricularly.
- the methods may also include a step of assessing cognitive function of the subject after administration of the HDAC2 inhibitor. Further the method may involve monitoring treatment by assessing cerebral blood flow or blood-brain barrier function.
- a method for treating Alzheimer's disease by administering to a subject having
- an HDAC2 inhibitor in an amount effective to treat Alzheimer's disease is provided according to other aspects of the invention.
- the HDAC2 inhibitor is a selective HDAC2 inhibitor.
- the HDAC2 inhibitor is a selective HDAC1/HDAC2 inhibitor. In other embodiments the HDAC2 inhibitor is a selective HDAC1/HDAC2 inhibitor.
- the HDAC2 inhibitor is a selective HDAC 1 /HDAC2/HDAC 10 inhibitor. In some embodiments, the selective HDAC1/HDAC2/HDAC10 inhibitor is BRD-6929. In other embodiments, the HDAC2 inhibitor is a selective HDAC1/HDAC2/HDAC3/HDAC10 inhibitor.
- the HDAC2 inhibitor is a compound of formula (IV)
- Ri and R 2 are independently selected from H, and -C(O)- R 3 is optionally substituted aryl, optionally substituted heteroaryl, or aryl-Ci- 6 alkylene.
- Ri is H; Rj and R 2 are H; Ri is -C(O)-C]. 6 alkyl; Ri is - C(O)-methyl; Ri is -C(O)-methyl and R 2 is H; R 3 is optionally substituted aryl; R 3 is tolyl; R 3 is optionally substituted heteroaryl; R 3 is thienyl; R 3 is aryl-Ci- ⁇ alkylene; or R 3 is phenyl-ethylene.
- the HDAC2 inhibitor in other embodiments is a compound of formula (VI)
- Ri and R 2 are independently selected from H, substituted or unsubstituted, branched or unbranched, cyclic or acyclic Ci-6alkyl, heterocyclyl, heteroaryl, aryl, and aryl-Ci -6 alkylene.
- Ri is H; Ri and R 2 are H: Ri is methyl, ethyl, propyl, or butyl; Ri is aryl- Ci_6alkylene; Ri is phenyl-ethylene; or R 2 is H.
- formula VI is
- the HDAC2 inhibitor in other embodiments is a compound of formula (I)
- Ri and R 2 are independently selected from H, substituted or unsubstituted, branched or unbranched, cyclic or acyclic heterocyclyl, Ci- ⁇ alkylene, heteroaryl, heteroarylene, and heteroarylene-alkylene; and R 3 is aryl or heteroaryl.
- Ri is unsubstituted acyclic Ri is selected from a group consisting of methyl, ethyl, propyl, and butyl; Ri is heteroarylene-alkylene; Ri is heteroarylene-Ci ⁇ alkylene; Ri is pyridinyl-ethylene; R 2 is hydrogen; R 3 is heteroaryl; or R 3 is thienyl.
- the HDAC2 inhibitor in some embodiments is a compound of formula (II)
- Ri and R 2 are independently selected from H, substituted or unsubstituted, branched or unbranched, cyclic or acyclic Ci ⁇ alkyl, heterocyclyl, Ci- ⁇ alkylene, heteroaryl, heteroarylene, heteroarylene-alkylene, arylene-alkylene; and heterocyclyl-alkylene optionally substituted; and R 3 is aryl or heteroaryl.
- Ri is unsubstituted acyclic C h alky); Ri is selected from a group consisting of methyl, ethyl, propyl, and butyl; Rj is heteroarylene-alkylene; Ri is heteroarylene-Ci. 6 alkylene; Rj is pyridinyl-ethylene; Ri is arylene-alkylene; Ri is arylene-Cl-6alkylene; Ri is phenyl-ethylene; Ri is heterocyclyl-alkylene;Ri is unsubstituted heterocyclyl-Ci.
- Ri is piperazine-ethylene; Ri is substituted heterocyclyl-Ci-6alkylene; Ri is substituted piperazine-ethylene; Ri is C ⁇ alkylene substituted piperazine-ethylene; Ri is methyl substituted piperazine-ethylene; R 2 is hydrogen; R 3 is heteroaryl; R 3 is thienyl; or R 3 is pyridinyl.
- formula II is
- the HDAC2 inhibitor in some embodiments is a compound of formula (III)
- Ri and R 2 are independently selected from H, and substituted or unsubstituted, branched or unbranched, cyclic or acyclic Ci -6 alkyl; and R 3 is alkynyl, aryl, or heteroaryl.
- X is -C(O)-N(Ri)(R 2 ); Ri and R 2 are independently selected from H, unsubstituted, unbranched, acyclic Ci- ⁇ alkyl; Ri and R 2 are independently selected from H, methyl, ethyl, propyl, and butyl; Ri is H; Ri and R 2 are H; X is -C(O)-NH 2 ; X is C, -6 akylene-N(Ri)-C,-6alkylene-N(R,)C(O)(R 2 ); R, is H; X is C, -6 akylene-N(H)-C,.
- Ri is HjR 1 is unsubstituted acyclic Ri is selected from a group consisting of methyl, ethyl, propyl, and butyl; R 2 is unsubstituted acyclic C h alky; R 2 is selected from a group consisting of methyl, ethyl, propyl, and butyl; R 3 is heteroaryl; R 3 is thienyl; R 3 is aryl; R 3 is alkynyl; R 3 is Ci_ 6 alkynyl; or R 3 is ethynyl.
- formula III is
- the HDAC2 inhibitor in other embodiments is a compound of formula (V)
- Ri and R 2 are independently selected from H, and substituted or unsubstituted, branched or unbranched, cyclic or acyclic Ci ⁇ alkyl; and R 3 is aryl or heteroaryl.
- Ri is H; Ri and R 2 are H; R] is methyl, ethyl, propyl, or butyl; R3 is aryl; R 3 is heteroaryl; or R3 is thienyl.
- formula V is
- the methods specifically exclude the use of molecules of Formula IV.
- Pharmaceutical compositions of a HDAC2 inhibitor and a pharmaceutically acceptable carrier in a formulation for delivery to brain tissue are also provided.
- the HDAC2 inhibitor is formulated for crossing blood brain barrier.
- the invention is a composition of an HDAC2 inhibitor, wherein the HDAC2 inhibitor is selected from the group consisting of compounds of formula I, II and III.
- Figure 1 shows HDAC inhibitor improved associative learning via HDAC2.
- b CAl region (pyramidal neuron layer; stratum radiatum (s.r.)) from WT and HDAC2OE mice received chronic SAHA treatment or saline treatment and were observed through immunostaining.
- FIG. 2 Increased ⁇ -Tubulin(K40) acetylation resulting from HDAC6 inhibition does not facilitate associative learning in mice.
- a. The structure of WT-161 is shown
- b. Selectivity of WT-161 (2 ⁇ M) for increasing acetylated ⁇ -tubulin(K40) over total acetylated lysine (Ac-lysine) was measured in human MMl .
- S cells treated for 16 hrs and assessed for hyperacetylated histones and/or ⁇ -tubulin(K40) using quantitative immunofluorescence imaging. Data presented are derived from a primary screen of a library of compounds biased for deacetylase function, c.
- FIG. 3 Expression and distribution of HDACl and HDAC2 in HDAClOE and HDAC2OE mouse brain
- a Representative immunostaining images showing the expression of HDACl in the WT and HDAClOE mice brain are provided. In WT brain, HDACl expression level is relatively higher in dentate gyrus than other areas of the brain. Increased HDACl signal in HDAClOE brain is detected not only in the hippocampus but also in the cortex, amygdala (indicated with dashed lines) and basal forebrain.
- Representative immunostaining images showing the expression of HDAC2 in WT and HDAC2OE mice brain are presented. Scale bar, 400 ⁇ m. Scale bar for insertion, 100 ⁇ m.
- FIG. 5 Characterization of HDAC2KO mice.
- a Schematic representation of the murine Hdac2 genomic locus is shown. Gray filled boxes indicate exons. Black arrowheads indicate lox? positions.
- P14F, Pl 5R and P2 are oligo DNA primers used for genotyping.
- b Westernblot analysis of protein lysates obtained from wild-type, Hdac2 + and Hdac2 L MEFs infected with either vector (V) or Cre-recombinase expressing retroviruses, using HDAC2 specific antibodies was performed.
- Cdk4 served as a loading control, c.
- Hdac2 +/ ⁇ and Hdac2 ⁇ / ⁇ mice obtained from multiple Hdac2 +/ ⁇ intercrosses, d.
- Western blot analysis of HDACl and HDAC2 expression levels in the brain lysate from the Hdac2 " mouse and WT littermate was performed. HDACl expression level was increased in Hdac2 ⁇ / ⁇ mice.
- SAHA treatment facilitates LTP in WT but not HDAC2K0 hippocampus, a-b.
- HDAC2KO mice and their WT littermates were injected with SAHA (25 mg/kg, i.p.) or saline for 10 days. An additional injection was introduced 30 minutes before sacrifice.
- Long-term potentiation (LTP) was induced by one HFS stimulation (1 x 100Hz, I s) of Schaffer collaterals, a.
- a significant increase in the magnitude of LTP was observed in the SAHA treated WT mice when compared to the saline group, b. No significant difference in the magnitude of LTP was detected between SAHA and saline treated HDAC2KO mice. (**, p ⁇ 0.005, two-way ANOVA).
- Figure 7 is a bar graph depicting the results of in vitro assays testing the protective effects of HDAC over expression on p25 induced toxicity.
- Neurons were dissociated from El 5.5 cortex and hippocampus and transfected with plasmids encoding p25-GFP and Flag-HDACs at DIV4. 24hrs after transfection, neurons were fixed and processed for IHC. All p25 positive neurons were counted, assuming most neurons are transfected by both p25 and HDACs.
- Figure 8 is a table which shows the enzymatic inhibitory activity of multiple
- HDAC inhibitors against several of the known HDAC iso forms are known HDAC inhibitors against several of the known HDAC iso forms.
- Figure 9 shows the effects of HDAC inhibitors on histone acetylation marks in HeLa cell lysate.
- Series of compounds incubated with whole HEK293 cells at 10 uM for a 6 hour time period.
- Western blot showing increased acetylation levels over DMSO controls using anti-acetyl H4K12 antibodies and horseradish peroxidase conjugated secondary antibody along with a luminol-based substrate. This demonstrates cellular HDAC activity of these analogs and the increase in acetylation in the specific mark, H4K12.
- Figure 10 is the quantification of the raw western data shown in Figure 9. Relative to the DMSO control, multiple selectivity profiles are effective in increasing H4K12 acetylation levels. This demonstrates that HDAC 1,2 and HDAC 1,2,3 selective inhibitors have robust HDAC activity in whole cells on a specific histone loci (H4K12). BRD-9853 shows minimal activity in this cell line. BRD-4097 is the negative control. This is a benzamide with minimal HDAC inhibitory activity.
- Figure 1 1 is the quantification of the raw western blots used to measure the effects of HDAC inhibitors on histone acetylation marks in HeLa cell lysate. Relative to the DMSO control, there are varying degrees of acetylation. The histogram demonstrates that HDAC 1,2 and HDAC 1,2,3 selective compounds are effective at increasing the acetylation at the H4K12 loci.
- Figure 12 shows the increased H4K12 acetylation in mouse primary striatal cells.
- Figure 13 shows that treatment of neuronal cells with BRD-6929 and BRD-5298 enhances H4 and H2B histone acetylation in vitro.
- Figures 14 demonstrates the nuclear intensity of increased H4K12-acetylation in mouse primary neuronal cultures.
- A Control demonstrating that BRD-6929 at 1 and 10 uM does not cause an increase or decrease in overall cell number after 6 h incubation in brain region specific primary cultures (cortex and striatum).
- B Histograms showing that BRD-6929 at 10 uM causes an increase in H4K12 acetylation after 6 h incubation in brain region specific primary cultures (striatum).
- An HDAC 1,2 selective compound is effective at increasing acetylation at a specific histone locus (H4K12) in cultured striatal neurons.
- Figure 15 demonstrates that an HDAC 1,2 selective compound can significantly increase acetylation marks associated with memory and learning in neuronal cells isolated from specific brain regions and analyzed using immunofluorescence.
- Figure 16 demonstrates that HDAC 1,2 selective compounds are effective in increasing the acetylation at the specific histone locus H2B.
- A Micrograph showing the increased fluorescence in primary neuronal cells after treatment with DMSO or 10 uM BRD-5298, an HDAC 1,2 selective inhibitor, after 6 h incubation. The increased magenta fluorescence corresponds to increased levels of H2B acetylation.
- B Control demonstrating that BRD-6929 and BRD-5298 at 1 and 10 uM do not cause an increase or decrease in overall cell number after 6 h incubation in primary neuronal cell cultures.
- C C.
- FIG. 17 is the concentration-time curve of BRD-6929 in plasma and brain following single 45 mg/kg i.p. dose in mice.
- Figure 18 is the experimental protocol for acute treatment with BRD-6929 and the corresponding effects on histone acytlation in brain specific regions of adult male C57BL/6J mice.
- FIG 19 shows that acute treatment with BRD-6929 causes H2B (tetra) histone acetylation in cortex of adult male C57BL/6J mice.
- the histograms on the left are the quantification of the western gel data shown on the right. The data has been normalized to the level of histone H3 levels.
- BRD-6929 causes a 1.5-2 fold increase in cortex for this mark. This demonstrates that BRD-6929 is a functional inhibitor of FIDACs in the cortex after a single dose given systemically.
- Figure 20 shows that acute treatment with BRD-6929 causes increased H2BK5 histone acetylation in cortex of adult male C57BL/6J mice.
- BRD- 6929 causes a 1.5-2 fold increase in the acetylation levels for H2BK5. This acetylation mark has been associated with increased learning and memory.
- Figure 21 demonstrates the increase in acetylation marks in whole brain after chronic administration of BRD-6929.
- Figure 22 demonstrates that BD-6929 increased associative learning and memory in WT C57/BL6 mice.
- HDACis histone deacetylases
- HDACi treatment failed to further facilitate memory formation in HDAC2 deficient mice.
- analysis of promoter occupancy revealed HDAC2 associates with the promoter of genes implicated in synaptic plasticity and memory formation.
- HDAC2 plays a role in modulating long lasting changes of the synapse, which in turn negatively regulates learning and memory.
- the invention relates in some aspects to therapeutics for enhancing and/or retrieving memories as well as promoting learning and memory.
- a "memory” as used herein refers to the ability to recover information about past events or knowledge. Memories include short-term memory (also referred to as working or recent memory) and long-term memory. Short-term memories involve recent events, while long-term memories relate to the recall of events of the more distant past.
- Enhancing or retrieving memories is distinct from learning. However, in some instances in the art learning is referred to as memory.
- the present invention distinguishes between learning and memory and is focused on enhancing memories. Learning, unlike memory enhancement, refers to the ability to create new memories that had not previously existed.
- the invention also relates to methods for enhancing learning.
- the therapeutic would be administered prior to or at the same time as the memory is created.
- the therapeutic is administered after the memory is created and preferably after the memory is lost.
- the invention relates to methods for recapturing a memory in a subject.
- a lost memory is one which cannot be retrieved by the subject without assistance, such as the therapeutic of the invention. In other words the subject cannot recall the memory.
- the term "recapture” refers to the ability of a subject to recall a memory that the subject was previously unable to recall. Generally, such a subject has a condition referred to as memory loss.
- a subject having memory loss is a subject that cannot recall one or more memories.
- the memories may be short term memories or long term memories. Methods for assessing the ability to recall a memory are known to those of skill in the art and may include routine cognitive tests. In other instances the invention relates to a method for accessing long-term memory in a subject having diminished access to a long-term memory.
- a subject having diminished access to a memory is a subject that has experienced one or more long term memory lapses.
- the long-term memory lapse may be intermittent or continuous.
- a subject having diminished access to a long term memory includes but is not limited to a subject having memory loss, with respect to long term memories.
- the long-term memory of the "subject having diminished access” may be impaired.
- An impaired long-term memory is one in which a physiological condition of the subject is associated with the long-term memory loss.
- Conditions associated with long-term memory loss include but are not limited to age related memory loss and injury related memory loss.
- age related memory loss refers to any of a continuum of conditions characterized by a deterioration of neurological functioning that does not rise to the level of a dementia, as further defined herein and/or as defined by the Diagnostic and Statistical Manual of Mental Disorders: 4th Edition of the American Psychiatric Association (DSM-IV, 1994). This term specifically excludes age-related dementias such as Alzheimer's disease and Parkinson's disease, and conditions of mental retardation such as Down's syndrome.
- Age related memory loss is characterized by objective loss of memory in an older subject compared to his or her younger years, but cognitive test performance that is within normal limits for the subject's age.
- Age-related memory loss may include decreased brain weight, gyral atrophy, ventricular dilation, and selective loss of neurons within different brain regions. For purposes of some embodiments of the present invention, more progressive forms of memory loss are also included under the definition of age-related memory disorder.
- persons having greater than age-normal memory loss and cognitive impairment, yet scoring below the diagnostic threshold for frank dementia may be referred to as having a mild neurocognitive disorder, mild cognitive impairment, late-life forgetfulness, benign senescent forgetfulness, incipient dementia, provisional dementia, and the like.
- Such subjects may be slightly more susceptible to developing frank dementia in later life (See also US patent application 2006/008517, which is incorporated by reference).
- Symptoms associated with age-related memory loss include but are not limited to alterations in biochemical markers associated with the aging brain, such as IL- lbeta, IFN-gamma, p-JNK, p-ERK, reduction in synaptic activity or function, such as synaptic plasticity, evidenced by reduction in long term potentiation, diminution of memory and reduction of cognition.
- injury related memory loss refers to damage which occurs to the brain, and which may result in neurological damage.
- Sources of brain injury include traumatic brain injury such as concussive injuries or penetrating head wounds, brain tumors, alcoholism, Alzheimer's disease, stroke, heart attack and other conditions that deprive the brain of oxygen, meningitis, AIDS, viral encephalitis, and hydrocephalus.
- a subject shall mean a human or vertebrate animal or mammal including but not limited to a dog, cat, horse, cow, pig, sheep, goat, turkey, chicken, and primate, e.g., monkey.
- Subjects are those which are not otherwise in need of an HDAC inhibitor.
- Subjects specifically exclude subjects having Alzheimer's disease, except in the instance where a subject having Alzheimer's disease is explicitly recited.
- the methods of the invention generally relate to methods for enhancing memories.
- Methods for enhancing memories include reestablishing access to memories as well as recapturing memories.
- the term re-establishing access as used herein refers to increasing retrieval of a memory.
- Applicants are not bound by a mechanism of action, it is believed that the compounds of the invention are effective in increasing retrieval of memories by re-establishing a synaptic network.
- the process of reestablishing a synaptic network may include an increase in the number of active brain synapses and or a reversal of neuronal loss.
- the term re-establish access to long-term memory when used with respect to a disorder comprising memory loss or memory lapse refers to a treatment which increases the ability of a subject to recall a memory.
- the therapeutic of the invention also decreases the incidence and/or frequency with which the memory is lost or cannot be retrieved.
- a subject in need of enhanced memories is one having memory loss or memory lapse.
- the memory loss may occur by any mechanism, such as it may be age related or caused by injury or disorders associated with cognitive impairment.
- Disorders associated with cognitive impairment include for instance MCI (mild cognitive impairment), Alzheimer's Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, vascular dementia, progressive supranuclear palsy or cortical basal degeneration.
- Alzheimer's disease is a degenerative brain disorder characterized by cognitive and noncognitive neuropsychiatric symptoms, which accounts for approximately 60% of all cases of dementia for patients over 65 years old. In Alzheimer's disease the cognitive systems that control memory have been damaged. Often long-term memory is retained while short-term memory is lost; conversely, memories may become confused, resulting in mistakes in recognizing people or places that should be familiar. Psychiatric symptoms are common in Alzheimer's disease, with psychosis (hallucinations and delusions) present in many patients. It is possible that the psychotic symptoms of Alzheimer's disease involve a shift in the concentration of dopamine or acetylcholine, which may augment a dopaminergic/cholinergic balance, thereby resulting in psychotic behavior.
- an increased dopamine release may be responsible for the positive symptoms of schizophrenia. This may result in a positive disruption of the dopaminergic/cholinergic balance.
- the reduction in cholinergic neurons effectively reduces acetylcholine release resulting in a negative disruption of the dopaminergic/cholinergic balance.
- antipsychotic agents that are used to relieve psychosis of schizophrenia are also useful in alleviating psychosis in Alzheimer's patients and could be combined with the compositions described herein for use in the methods of the invention.
- Methods for recapturing a memory in a subject having Alzheimer's disease by administering an HDAC inhibitor are also provided according to the invention. Such methods optionally administering the inhibitor and monitoring the subject to identify recapture of a memory that was previously lost. Subjects may be monitored by routine tests known in the art. For instance some are described in books such as DSM described above or in the medical literature.
- vascular dementia also referred to as “multi-infarct dementia” refers to a group of syndromes caused by different mechanisms all resulting in vascular lesions in the brain.
- vascular dementia The main subtypes of vascular dementia are, for example vascular mild cognitive impairment, multi-infarct dementia, vascular dementia due to a strategic single infarct (affecting the thalamus, the anterior cerebral artery, the parietal lobes or the cingulate gyrus), vascular dementia due to hemorrhagic lesions, small vessel disease (including, e.g. vascular dementia due to lacunar lesions and Binswanger disease), and mixed Alzheimer's Disease with vascular dementia.
- HDACs interact with other chromatin-modifying enzymes and co-regulators and play a key role in shaping epigenetic landscapes (Goldberg, A. D., Allis, C. D., & Bernstein, E. Cell 128 (4), 635-638 (2007).).
- HDAC enzymes There are a total of 18 HDAC enzymes in the mammalian genome, which are generally divided into four classes including class I, II, III and IV. These enzymes are known to have both histone and non-histone substrates. With the exception of the class II HDAC5, which has recently been implicated in the response to both antidepressant action (Tsankova, N. M. et al.
- HDACs Class I, II and IV HDACs are the zinc-dependent hydrolases.
- Class I HDACs include 1, 2, 3, and 8, which have been well documented to exert deacetylase activity on histone substrates as well as non-histone substrates. These family members are all inhibited by the non-selective HDAC inhibitor sodium butyrate.
- Class II HDACs can be divided into Class Ha members, which include HDAC 4, 5, 7 and 9, and Class Hb members, which include HDAC6 and 10.
- HDAC5 a role in the brain has been identified in response to both antidepressant action and to chronic emotional stimuli.
- class Ha HDACs themselves have functional histone (or other non-histone) deacetylates activity, rather than activity contributed by co-purifying class I HDACs, currently remains unclear.
- Class lib family members, HDAC6 and 10 are mainly localized in the cytoplasm.
- HDAC6 is unique in the family in its possession of two deacetylase domains. HDAC6 has been shown to function as both an ⁇ -tublin (K40) deacetylase and to regulate ubiquitin-dependent protein degradation by the proteasome.
- class III HDACs are non-classical, NAD(+)-dependent enzymes, which exhibit a non-overlapping sensitivity to most structural classes of inhibitors of zinc-dependent HDACs, including SB.
- the latter finding suggests the sirtuins are not the relevant targets of HDACi induced memory enhancement.
- the compounds useful according to the invention are HDAC2 inhibitors.
- An HDAC2 inhibitor as used herein is any compound, including proteins, small molecules, and nucleic acids, that reduces HDAC2 activity and/or expression.
- HDAC2 inhibitors may in some embodiments be selective HDAC2 inhibitors.
- a selective HDAC2 inhibitor is a compound that inhibits the activity or expression of HDAC2 but does not significantly inhibit the activity or expression of at least 2 other HDAC enzymes such as HDACl, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAClO, HDACl 1, HDAC 12, HDAC13, HDAC14, HDAC15, HDAC16, HDAC17, or HDAC18.
- a selective HDAC2 inhibitor is a compound that inhibits the activity or expression of HDAC2 but does not significantly inhibit the activity or expression of any other HDAC enzymes.
- a selective HDAC2 inhibitor does not significantly inhibit the activity or expression of any other class I HDAC enzymes.
- An HDAC1/HDAC2 selective inhibitor is a compound that inhibits the activity or expression of HDACl and HDAC2 but does not significantly inhibit the activity or expression of at least one non-class I HDAC enzyme. In some embodiments an HDAC1/HDAC2 selective inhibitor does not significantly inhibit the activity or expression of any non-class I HDAC enzyme. In other embodiments an HDAC1/HDAC2 selective inhibitor does not significantly inhibit the activity or expression of a HDAC3 enzyme.
- An HDAC1/HDAC2/HDAC3 selective inhibitor is a compound that inhibits the activity or expression of HDACl and HDAC2 and HDAC3 but does not significantly inhibit the activity or expression of at least one non-class I HDAC enzyme.
- an HDAC1/HDAC2/HDAC3 selective inhibitor does not significantly inhibit the activity or expression of any non-class I HDAC enzyme. Significantly inhibit refers to an amount that would detectably alter the activity of the HDAC in a cell such as in vivo.
- the non-selective HDAC2 inhibitor may be partially selective. For instance, it may act as an inhibitor of one or more other enzymes of HDACl -HDAC 18 but not all.
- the HDAC inhibitor does not act as an inhibitor of HDACl, HDAC5, HDAC6, HDAC7, and HDAClO.
- the HDAC2 inhibitor is a selective HDAC1/HDAC2/HDAC10 inhibitor.
- the selective HDAC1/HDAC2/HDAC10 inhibitor is BRD-6929.
- the HDAC2 inhibitor is a selective HDAC1/HDAC2/HDAC3/HDAC10 inhibitor.
- HDAC2 inhibitors include binding peptides such as antibodies, preferably monoclonal antibodies, antibody fragments, scFv, etc that specifically react with the histone deacetylase, small molecule inhibitors (often classically referred to as HDAC inhibitors), and expression inhibitors such as antisense and siRNA. Studies described in the Examples below were also undertaken to determine which of the 1 1 histone deacetylases is responsible for the observed function and to identify selective HDAC inhibitors for enhancing memory.
- HDAC2 Tg mice do not show any difference in learning behavior compared to the control mice, HDAC2 Tg mice have impaired learning as evaluated by Pavlovian fear conditioning and Morris water maze tests. Remarkably, HDAC2 neuron specific knockout mice (loss of function) display enhanced learning. Conversely, MS-275, a class 1 HDAC inhibitor (HDAC 1/HDAC3 specific), did not facilitate associative learning in mice and MS-275 treated mice showed lower number of c-fos positive cells after fear conditioning training compared to saline treated group. Additional data also demonstrates that HDAC5, HDAC6, HDAC7 and HDAClO are not useful for enhancing memory.
- HDAC2 participates in learning and memory and that it is likely to be the target of inhibition by the general HDAC inhibitors. Even more surprisingly it was discovered that HDAC1/HDAC2 and HDACl /HD AC2/HDAC3 selective inhibitors were also useful in enhancing learning and memory. Prior studies by some of the instant inventors had demonstrated that HDACl activators promote neurogenesis. Thus it was unexpected that HDAC1/HDAC2 inhibitors would be useful for enhancing memory.
- HDAC inhibitors include but are not limited to the following compounds, functional analogs and salts thereof: trichostatin A (TSA), trichostatin B, trichostatin C, trapoxin A, trapoxin B, chlamydocin, sodium salts of butyrate, butyric acid, sodium salts of phenylbutyrate, phenylbutyric acid, scriptaid, FR901228, depudecin, oxamflatin, pyroxamide, apicidin B, apicidin C, Helminthsporium carbonum toxin, 2-amino-8-oxo- 9,10-epoxy-decanoyl, 3-(4-aroyl-lH-pyrrol-2-yl)-N-hydroxy-2-propenamide, suberoylanilide hydroxamic acid (SAHA), valproic acid, FK228, or m-carboxycinnamic acid bis-hydroxamide.
- TSA trichostatin A
- the HDAC inhibitor is an HDAC2 inhibitor such as sodium butyrate, SAHA or TSA.
- HDAC2 inhibitor such as sodium butyrate, SAHA or TSA.
- Derivatives of the inhibitors showing increased pharmacological half-life are also useful according to the invention (Brettman and Chaturvedi, J. CIi. Pharmacol. 36 (1996), 617-622).
- SAHA pan or universal HDAC inhibitor
- SAHA refers to suberoylanilide hydroxamic acid, analogs, derivatives and polymorphs. Polymorphs of SAHA are described in US Published Patent Application No. 20040122101 which is incorporated by reference.
- HDAC2 inhibitors including HDAC2 selective inhibitors, HDACl /HD AC2 selective inhibitors and HDACl /HD AC2/HDAC3 selective inhibitors, of the invention include small molecules as well as inhibitory nucleic acids such as antisense and siRNA.
- Small molecule HDAC2 inhibitors include for instance compounds of the following formulas:
- Ri and R 2 are independently selected from H, substituted or unsubstituted, branched or unbranched, cyclic or acyclic Ci ⁇ alkyl, heterocyclyl, Ci- ⁇ alkylene, heteroaryl, heteroarylene, and heteroarylene-alkylene; and R 3 is aryl or heteroaryl.
- Ri is unsubstituted acyclic C ⁇ alkyl; Ri is selected from a group consisting of methyl, ethyl, propyl, and butyl; Ri is heteroarylene- alkylene; Ri is heteroarylene-Ci- 6 alkylene; Ri is pyridinyl-ethylene; R 2 is hydrogen; R 3 is heteroaryl; or R 3 is thienyl.
- Ri and R 2 are independently selected from H, substituted or unsubstituted, branched or unbranched, cyclic or acyclic Ci. 6 alkyl, heterocyclyl, C)- ⁇ alkylene, heteroaryl, heteroarylene, heteroarylene-alkylene, arylene-alkylene; and heterocyclyl-alkylene optionally substituted; and R 3 is aryl or heteroaryl.
- Ri is unsubstituted acyclic Ci ⁇ alkyl
- Ri is selected from a group consisting of methyl, ethyl, propyl, and butyl
- is heteroarylene-alkylene
- Ri is heteroarylene-Ci.
- Ri is pyridinyl-ethylene; Ri is arylene-alkylene; Ri is arylene-Cl-6alkylene; Ri is phenyl-ethylene; Ri is heterocyclyl-alkylene;Ri is unsubstituted heterocyclyl-C). 6 alkylene; Ri is piperazine-ethylene; Ri is substituted heterocyclyl-Ci- ⁇ alkylene; Ri is substituted piperazine-ethylene; Ri is substituted piperazine-ethylene; Ri is methyl substituted piperazine-ethylene; R 2 is hydrogen; R 3 is heteroaryl; R 3 is thienyl; or R 3 is pyridinyl.
- X is -C(O)-N(Ri)(R 2 ), Ci -6 akylene-N(H)-Ci -6 alkylene-N(Ri)C(O)(R 2 ); or -N(Ri)C(O)R 2 ;
- Ri and R 2 are independently selected from H, and substituted or unsubstituted, branched or unbranched, cyclic or acyclic Q ⁇ alkyl; and R 3 is alkynyl, aryl, or heteroaryl.
- X is -C(O)-N(Ri)(R 2 ); Ri and R 2 are independently selected from H, unsubstituted, unbranched, acyclic Ci ⁇ alkyl; Ri and R 2 are independently selected from H, methyl, ethyl, propyl, and butyl; Ri is H; Ri and R 2 are H; X is -C(O)-NH 2 ; X is Ci -6 akylene-N(Ri)-Ci -6 alkylene-N(R,)C(O)(R 2 ); R, is H; X is Ci -6 akylene-N(H)-Ci -6 alkylene-N(H)C(O)(R 2 ); X is -N(Ri)C(O)R 2 ; R, is H;R, is unsubstituted acyclic Ci ⁇ alkyl; Ri is selected from a group consisting of methyl, ethyl, propyl, and
- R) and R 2 are independently selected from H, and -C(O)- Ci ⁇ alkyl; R 3 is optionally substituted aryl, optionally substituted heteroaryl, or aryl-Ci- ⁇ alkylene.
- Ri is H; Ri and R 2 are H; Ri is -C(0)-Ci. 6 alkyl; Ri is -C(O)-methyl; Ri is -C(O)-methyl and R 2 is H; R 3 is optionally substituted aryl; R 3 is tolyl; R 3 is optionally substituted heteroaryl; R 3 is thienyl; R 3 is aryl-Ci- ⁇ alkylene; or R 3 is phenyl- ethylene.
- Ri and R 2 are independently selected from H, and substituted or unsubstituted, branched or unbranched, cyclic or acyclic Q ⁇ alkyl; and R 3 is aryl or heteroaryl.
- Ri is H; Ri and R 2 are H; Ri is methyl, ethyl, propyl, or butyl; R 3 is aryl; R 3 is heteroaryl; or R 3 is thienyl.
- Ri and R 2 are independently selected from H, substituted or unsubstituted, branched or unbranched, cyclic or acyclic Ci- ⁇ alkyl, heterocyclyl, heteroaryl, aryl, and aryl-Ci. 6 alkylene.
- Ri is H; Ri and R 2 are H: Ri is methyl, ethyl, propyl, or butyl; Ri is aryl- Ci ⁇ alkylene; Ri is phenyl-ethylene; or R 2 is H.
- Alkyl in general, refers to an aliphatic hydrocarbon group which may be straight, branched or cyclic having from 1 to about 10 carbon atoms in the chain, and all combinations and sub combinations of ranges therein.
- alkyl includes both "unsubstituted alkyls” and “substituted alkyls,” the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the backbone.
- a straight chain or branched chain alkyl has 12 or fewer carbon atoms in its backbone (e.g., Ci-Ci 2 for straight chain, C 3 -Ci 2 for branched chain), and more preferably 6 or fewer, and even more preferably 4 or fewer.
- preferred cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 5, 6 or 7 carbons in the ring structure.
- lower alkyl as used herein means an alkyl group, as defined above, but having from one to ten carbons, more preferably from one to six carbon atoms in its backbone structure, and even more preferably from one to four carbon atoms in its backbone structure.
- lower alkenyl and “lower alkynyl” have similar chain lengths.
- Preferred alkyl groups are lower alkyls.
- a substituent designated herein as alkyl is a lower alkyl.
- Alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, cyclopentyl, isopentyl, neopentyl, n-hexyl, isohexyl, cyclohexyl, cyclooctyl, adamantyl, 3-methylpentyl, 2, 2-dimethylbutyl, and 2,3-dimethylbutyl.
- Alkyl substituents can include, for example, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate,
- halogen designates -F, -Cl, -Br or -I
- sulfhydryl means -SH
- hydroxyl means -OH.
- aryl alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused.
- aryl embraces aromatic radicals such as phenyl, naphthyl, tetrahydronapthyl, indane and biphenyl, and includes carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally substituted.
- aryl as used herein includes 5-, 6- and 7-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like.
- aryl groups having heteroatoms in the ring structure may also be referred to as "aryl heterocycles" or “heteroaromatics.”
- the aromatic ring can be substituted at one or more ring positions with such substituents as described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, -CF 3 , -CN, or the like.
- aryl also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are "fused rings") wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls.
- biasing represents aryl groups which have 5-14 atoms containing more than one aromatic ring including both fused ring systems and aryl groups substituted with other aryl groups. Such groups may be optionally substituted. Suitable biaryl groups include naphthyl and biphenyl.
- carbocyclic refers to a cyclic compounds in which all of the ring members are carbon atoms. Such rings may be optionally substituted. The compound can be a single ring or a biaryl ring.
- cycloalkyl embraces radicals having three to ten carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and norboryl. Such groups may be substituted.
- Heterocyclic aryl or “heteroaryl” groups are groups which have 5-14 ring atoms wherein 1 to 4 heteroatoms are ring atoms in the aromatic ring and the remainder of the ring atoms being carbon atoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen. Suitable heteroaryl groups include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolyl, pyridyl-N-oxide, pyrimidyl, pyrazinyl, imidazolyl, indolyl and the like, all optionally substituted.
- heterocyclic refers to cyclic compounds having as ring members atoms of at least two different elements.
- the compound can be a single ring or a biaryl.
- Heterocyclic groups include, for example, thiophene, benzothiophene, thianthrene, furan, pyran, isobenzofuran, chromene, xanthene, phenoxathiin, pyrrole, imidazole, pyrazole, isothiazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine,
- the heterocyclic ring can be substituted at one or more positions with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, - CF 3 , -CN, or the like.
- substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carb
- substitution or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.
- substituted is contemplated to include all permissible substituents of organic compounds.
- the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds.
- Illustrative substituents include, for example, those described herein above.
- the permissible substituents can be one or more and the same or different for appropriate organic compounds.
- the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. This invention is not intended to be limited in any manner by the permissible substituents of organic compounds.
- HDAC2 inhibitors useful in the methods of the invention are:
- the compounds of the invention may optionally be administered with other compounds such as DNA methylation inhibitors.
- a DNA methylation inhibitor is an agent that directly or indirectly causes a reduction in the level of methylation of a nucleic acid molecule.
- DNA methylation inhibitors are well known and routinely utilized in the art and include, but are not limited to, inhibitors of methylating enzymes such as methylases and methyltransferases.
- Non-limiting examples of DNA methylation inhibitors include 5-azacytidine, 5-aza-2'deoxycytidine (also known as Decitabine in Europe), 5, 6-dihydro-5-azacytidine, 5, 6-dihydro-5-aza-2'deoxycytidine, 5- fluorocytidine, 5-fluoro-2'deoxycytidine, and short oligonucleotides containing 5-aza- 2'deoxycytosine, 5, 6-dihydro-5-aza-2'deoxycytosine, and 5-fluoro-2'deoxycytosine, and procainamide, Zebularine, and (-)-egallocatechin-3-gallate.
- HDAC2 can also be inhibited by nucleic acid based or expression inhibitors such as antisense and RNAi.
- nucleic acid based or expression inhibitors such as antisense and RNAi.
- the invention embraces inhibitory nucleic acids such as antisense oligonucleotides that selectively bind to nucleic acid molecules encoding HDAC2 to decrease expression and activity of this protein.
- antisense oligonucleotide or “antisense” describes an oligonucleotide that is an oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an mRNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA.
- the antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene or transcript.
- Antisense oligonucleotides that selectively bind to a nucleic acid molecule encoding a histone deacetylase are particularly preferred. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence.
- the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under physiological conditions, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions.
- the nucleotide sequences of nucleic acid molecules encoding histone deacetylase e.g., GenBank Accession Nos NP 848512, NP_848510, NP 478057, NP_478056, NP 055522
- allelic or homologous genomic and/or cDNA sequences one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention.
- antisense oligonucleotides should comprise at least about 10 and, more preferably, at least about 15 consecutive bases which are complementary to the target, although in certain cases modified oligonucleotides as short as 7 bases in length have been used successfully as antisense oligonucleotides. See Wagner et al., Nat. Med. 1(11):11 lol l 18, 1995. Most preferably, the antisense oligonucleotides comprise a complementary sequence of 20-30 bases.
- oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In addition, 3 '-untranslated regions may be targeted by antisense oligonucleotides. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., Cell MoI. Neurobiol. 14(5):439-457, 1994) and at which proteins are not expected to bind.
- the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage.
- These oligonucleotides may be prepared by art recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors.
- the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness.
- modified oligonucleotide as used herein describes an oligonucleotide in which (1) at least two of its nucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not normally associated with nucleic acid molecules has been covalently attached to the oligonucleotide.
- a synthetic internucleoside linkage i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide
- Preferred synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamidates, carboxymethyl esters and peptides.
- modified oligonucleotide also encompasses oligonucleotides with a covalently modified base and/or sugar.
- modified oligonucleotides include oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position.
- modified oligonucleotides may include a 2'-O-alkylated ribose group.
- modified oligonucleotides may include sugars such as arabinose instead of ribose.
- the present invention contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and hybridizable with, under physiological conditions, nucleic acid molecules encoding a histone deacetylase, together with pharmaceutically acceptable carriers.
- Antisense oligonucleotides may be administered as part of a pharmaceutical composition. In this latter embodiment, it may be preferable that a slow intravenous administration be used.
- Such a pharmaceutical composition may include the antisense oligonucleotides in combination with any standard physiologically and/or pharmaceutically acceptable carriers which are known in the art.
- the compositions should be sterile and contain a therapeutically effective amount of the antisense oligonucleotides in a unit of weight or volume suitable for administration to a subject.
- RNA interference RNA interference
- the processes of the invention also encompass use of isolated short RNA that directs the sequence-specific degradation of a histone deacetylase mRNA through a process known as RNA interference (RNAi).
- RNAi RNA interference
- the process is known to occur in a wide variety of organisms, including embryos of mammals and other vertebrates. It has been demonstrated that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length, and furthermore, that they mediate RNA interference in the absence of longer dsRNA. Thus, these 21-23 nt fragments are sequence-specific mediators of RNA degradation and are referred to herein as siRNA or RNAi.
- Methods of the invention encompass the use of these fragments (or recombinantly produced or chemically synthesized oligonucleotides of the same or similar nature) to enable the targeting of histone deacetylase mRNAs for degradation in mammalian cells useful in the therapeutic applications discussed herein.
- the invention features a siNA molecule having RNAi activity against target HDAC2 RNA (e.g., coding or non-coding RNA), wherein the siNA molecule comprises a sequence complementary to any HDAC2 RNA sequence, such as that sequence having HDAC2 GenBank Accession No: mRNA NM OO 1527 for homo sapiens. Chemical modifications can be applied to any siNA construct of the invention. As shown in GenBank Accession No: mRNA NM_001527 the protein sequence of HDAC2 is:
- the nucleic acid sequence is:
- small interfering nucleic acid that include, for example: microRNA (miRNA), small interfering RNA (siRNA), double-stranded RNA (dsRNA), and short hairpin RNA (shRNA) molecules.
- miRNA microRNA
- siRNA small interfering RNA
- dsRNA double-stranded RNA
- shRNA short hairpin RNA
- siNA of the invention can be unmodified or chemically- modified.
- siNA of the instant invention can be chemically synthesized, expressed from a vector or enzymatically synthesized as discussed herein.
- the instant invention also features various chemically-modified synthetic small interfering nucleic acid (siNA) molecules capable of modulating gene expression or activity in cells by RNA interference (RNAi).
- RNAi RNA interference
- siNA improves various properties of native siNA molecules through, for example, increased resistance to nuclease degradation in vivo and/or through improved cellular uptake. Furthermore, siNA having multiple chemical modifications may retain its RNAi activity.
- the siNA molecules of the instant invention provide useful reagents and methods for a variety of therapeutic applications.
- oligonucleotides are modified to enhance stability and/or enhance biological activity by modification with nuclease resistant groups, for example, 2'amino, 2'-C-allyl, 2'-flouro, 2'-O-methyl, 2'-H, nucleotide base modifications (for a review see Usman and Cedergren, 1992, TIBS. 17, 34; Usman et al., 1994, Nucleic Acids Symp. Ser. 31, 163; Burgin et al., 1996, Biochemistry , 35, 14090).
- nuclease resistant groups for example, 2'amino, 2'-C-allyl, 2'-flouro, 2'-O-methyl, 2'-H, nucleotide base modifications
- one of the strands of the double-stranded siNA molecule comprises a nucleotide sequence that is complementary to a nucleotide sequence of a target RNA or a portion thereof, and the second strand of the double-stranded siNA molecule comprises a nucleotide sequence identical to the nucleotide sequence or a portion thereof of the targeted RNA.
- one of the strands of the double-stranded siNA molecule comprises a nucleotide sequence that is substantially complementary to a nucleotide sequence of a target RNA or a portion thereof, and the second strand of the double-stranded siNA molecule comprises a nucleotide sequence substantially similar to the nucleotide sequence or a portion thereof of the target RNA.
- each strand of the siNA molecule comprises about 19 to about 23 nucleotides, and each strand comprises at least about 19 nucleotides that are complementary to the nucleotides of the other strand.
- an siNA is an shRNA, shRNA-mir, or microRNA molecule encoded by and expressed from a genomically integrated transgene or a plasmid-based expression vector.
- a molecule capable of inhibiting mRNA expression, or microRNA activity is a transgene or plasmid-based expression vector that encodes a small-interfering nucleic acid.
- Such transgenes and expression vectors can employ either polymerase II or polymerase III promoters to drive expression of these shRNAs and result in functional siRNAs in cells. The former polymerase permits the use of classic protein expression strategies, including inducible and tissue-specific expression systems.
- transgenes and expression vectors are controlled by tissue specific promoters.
- transgenes and expression vectors are controlled by inducible promoters, such as tetracycline inducible expression systems.
- a small interfering nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector.
- the recombinant mammalian expression vector may be capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue specific regulatory elements are known in the art.
- tissue-specific promoters include the myosin heavy chain promoter, albumin promoter, lymphoid-specific promoters, neuron specific promoters, pancreas specific promoters, and mammary gland specific promoters. Developmentally-regulated promoters are also encompassed, for example the murine hox promoters and the a-fetoprotein promoter.
- Other inhibitor molecules that can be used include ribozymes, peptides,
- DNAzymes peptide nucleic acids (PNAs), triple helix forming oligonucleotides, antibodies, and aptamers and modified form(s) thereof directed to sequences in gene(s), RNA transcripts, or proteins.
- Antisense and ribozyme suppression strategies have led to the reversal of a tumor phenotype by reducing expression of a gene product or by cleaving a mutant transcript at the site of the mutation (Carter and Lemoine Br. J.
- Ribozyme activity may be augmented by the use of, for example, non-specific nucleic acid binding proteins or facilitator oligonucleotides (Herschlag et al., Embo J.
- Multitarget ribozymes (connected or shotgun) have been suggested as a means of improving efficiency of ribozymes for gene suppression (Ohkawa et al., Nucleic Acids Symp Ser. (29): 121-2, 1993).
- Triple helix approaches have also been investigated for sequence-specific gene suppression. Triple helix forming oligonucleotides have been found in some cases to bind in a sequence-specific manner (Postel et al., Proc. Natl. Acad. Sci. U.S.A. 88(18):8227-31, 1991 ; Duval-Valentin et al., Proc. Natl. Acad. Sci. U.S.A. 89(2):504-8, 1992; Hardenbol and Van Dyke Proc. Natl. Acad. Sci. U.S.A. 93(7):281 1-6, 1996; Porumb et al., Cancer Res. 56(3):515-22, 1996).
- peptide nucleic acids have been shown to inhibit gene expression (Hanvey et al., Antisense Res. Dev. l (4):307-17, 1991 ; Knudsen and Nielson Nucleic Acids Res. 24(3):494-500, 1996; Taylor et al., Arch. Surg. 132(1 1): 1 177-83, 1997).
- Minor-groove binding polyamides can bind in a sequence-specific manner to DNA targets and hence may represent useful small molecules for future suppression at the DNA level (Trauger et al., Chem. Biol. 3(5):369- 77, 1996).
- suppression has been obtained by interference at the protein level using dominant negative mutant peptides and antibodies (Herskowitz Nature 329(6136):219-22, 1987; Rimsky et al., Nature 341(6241):453-6, 1989; Wright et al., Proc. Natl. Acad. Sci. U.S.A. 86(9):3199-203, 1989).
- suppression strategies have led to a reduction in RNA levels without a concomitant reduction in proteins, whereas in others, reductions in RNA have been mirrored by reductions in protein.
- the diverse array of suppression strategies that can be employed includes the use of DNA and/or RNA aptamers that can be selected to target, for example HDAC2. Suppression and replacement using aptamers for suppression in conjunction with a modified replacement gene and encoded protein that is refractory or partially refractory to aptamer-based suppression could be used in the invention.
- RNAs are preferably chemically synthesized using appropriately protected ribonucleoside phosphoramidites and a conventional DNA/RNA synthesizer. Most conveniently, siRNAs are obtained from commercial RNA oligo synthesis suppliers listed herein. In general, RNAs are not too difficult to synthesize and are readily provided in a quality suitable for RNAi.
- a typical 0.2 ⁇ mol-scale RNA synthesis provides about 1 milligram of RNA, which is sufficient for 1000 transfection experiments using a 24-well tissue culture plate format.
- the histone deacetylase cDNA specific siRNA is designed preferably by selecting a sequence that is not within 50-100 bp of the start codon and the termination codon, avoids intron regions, avoids stretches of 4 or more bases such as AAAA, CCCC, avoids regions with GC content ⁇ 30% or >60%, avoids repeats and low complex sequence, and it avoids single nucleotide polymorphism sites.
- the histone deacetylase siRNA may be designed by a search for a 23-nt sequence motif AA(N 19).
- a 23-nt sequence motif NA(N21) may be used with conversion of the 3' end of the sense siRNA to TT.
- the histone deacetylase siRNA can be designed by a search for NAR(N 17) YNN.
- the target sequence may have a GC content of around 50%.
- the siRNA targeted sequence may be further evaluated using a BLAST homology search to avoid off target effects on other genes or sequences.
- Negative controls are designed by scrambling targeted siRNA sequences.
- the control RNA preferably has the same length and nucleotide composition as the siRNA but has at least 4-5 bases mismatched to the siRNA.
- the RNA molecules of the present invention can comprise a 3' hydroxyl group.
- the RNA molecules can be single-stranded or double stranded; such molecules can be blunt ended or comprise overhanging ends (e.g., 5', 3') from about 1 to about 6 nucleotides in length (e.g., pyrimidine nucleotides, purine nucleotides).
- the 3' overhangs can be stabilized against degradation.
- the RNA can be stabilized by including purine nucleotides, such as adenosine or guanosine nucleotides.
- purine nucleotides such as adenosine or guanosine nucleotides.
- substitution of pyrimidine nucleotides by modified analogues e.g., substitution of uridine 2 nucleotide 3' overhangs by 2'-deoxythymidine is tolerated and does not affect the efficiency of RNAi.
- the absence of a 2' hydroxyl significantly enhances the nuclease resistance of the overhang in tissue culture medium.
- RNA molecules used in the methods of the present invention can be obtained using a number of techniques known to those of skill in the art.
- the RNA can be chemically synthesized or recombinantly produced using methods known in the art. Such methods are described in U.S. Published Patent Application Nos. US2002- 0086356A1 and US2003-0206884A1 that are hereby incorporated by reference in their entirety.
- RNA can be used in the methods of the present invention, provided that it has sufficient homology to the HDAC2 gene to mediate RNAi.
- the RNA for use in the present invention can correspond to the entire HDAC2 gene or a portion thereof. There is no upper limit on the length of the RNA that can be used. For example, the RNA can range from about 21 base pairs (bp) of the gene to the full length of the gene or more. In certain embodiments the preferred length of the RNA of the invention is 21 to 23 nucleotides.
- histone deacetylase DNA methylating enzymes can also be inhibited by binding peptides such as antibodies. Numerous histone deacetylase antibodies are commercially available from sources such as Sigma, Vinci Biochem, Cell Signaling Technologies.
- Such antibodies can be modified to produce antibody fragments or humanized versions.
- therapeutically useful antibodies can be produced using techniques known to those of ordinary skill in the art since HDACs are available.
- the therapeutic compounds of the invention may be directly administered to the subject or may be administered in conjunction with a delivery device or vehicle. Delivery vehicles or delivery devices for delivering therapeutic compounds to surfaces have been described.
- the therapeutic compounds of the invention may be administered alone (e.g., in saline or buffer) or using any delivery vehicles known in the art.
- the following delivery vehicles have been described: Cochleates; Emulsomes, ISCOMs; Liposomes; Live bacterial vectors (e.g., Salmonella, Escherichia coli, Bacillus calmatte-guerin, Shigella, Lactobacillus); Live viral vectors (e.g., Vaccinia, adenovirus, Herpes Simplex); Microspheres; Nucleic acid vaccines; Polymers; Polymer rings; Proteosomes; Sodium Fluoride; Transgenic plants; Virosomes; Virus-like particles.
- Live bacterial vectors e.g., Salmonella, Escherichia coli, Bacillus calmatte-guerin, Shigella, Lactobacillus
- Live viral vectors e.g., Vaccinia, adenovirus, Herpes Simplex
- Microspheres Nucleic acid vaccines
- Polymers Polymers
- Polymer rings Proteosomes
- Sodium Fluoride Transgenic plants
- an effective amount of a therapeutic compound of the invention refers to the amount necessary or sufficient to realize a desired biologic effect.
- an effective amount of a therapeutic compounds of the invention is that amount sufficient to re-establish access to a memory.
- an effective prophylactic or therapeutic treatment regimen can be planned which does not cause substantial toxicity and yet is entirely effective to treat the particular subject.
- the effective amount for any particular application can vary depending on such factors as the disease or condition being treated, the particular therapeutic compounds being administered the size of the subject, or the severity of the disease or condition.
- One of ordinary skill in the art can empirically determine the effective amount of a particular therapeutic compounds of the invention without necessitating undue experimentation.
- Compositions of the invention include compounds as described herein, or a pharmaceutically acceptable salt or hydrate thereof.
- Subject doses of the compounds described herein for delivery typically range from about 0.1 ⁇ g to 10 mg per administration, which depending on the application could be given daily, weekly, or monthly and any other amount of time therebetween.
- the doses for these purposes may range from about 10 ⁇ g to 5 mg per administration, and most typically from about 100 ⁇ g to 1 mg, with 2 - 4 administrations being spaced days or weeks apart.
- parenteral doses for these purposes may be used in a range of 5 to 10,000 times higher than the typical doses described above.
- the composition is administered once daily at a dose of about 200-600 mg. In another embodiment, the composition is administered twice daily at a dose of about 200-400 mg. In another embodiment, the composition is administered twice daily at a dose of about 200-400 mg intermittently, for example three, four, or five days per week. In another embodiment, the composition is administered three times daily at a dose of about 100-250 mg. In one embodiment, the daily dose is 200 mg, which can be administered once-daily, twice-daily, or three-times daily. In one embodiment, the daily dose is 300 mg, which can be administered once-daily or twice-daily. In one embodiment, the daily dose is 400 mg, which can be administered once-daily or twice- daily.
- the HDAC inhibitor can be administered in a total daily dose of up to 800 mg once, twice or three times daily, continuously (i.e., every day) or intermittently (e.g., 3-5 days a week).
- the therapeutically effective amount can be initially determined from animal models.
- a therapeutically effective dose can also be determined from human data for HDAC inhibitors which have been tested in humans (e.g. for the treatment of cancer) and for compounds which are known to exhibit similar pharmacological activities. Higher doses may be required for parenteral administration.
- the applied dose can be adjusted based on the relative bioavailability and potency of the administered compound. Adjusting the dose to achieve maximal efficacy based on the methods described above and other methods as are well-known in the art is well within the capabilities of the ordinarily skilled artisan.
- Toxicity and efficacy of the prophylactic and/or therapeutic protocols of the present invention can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD 50 /ED50.
- Prophylactic and/or therapeutic agents that exhibit large therapeutic indices are preferred. While prophylactic and/or therapeutic agents that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such agents to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
- the data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage of the prophylactic and/or therapeutic agents for use in humans.
- the dosage of such agents lies preferably within a range of circulating concentrations that include the ED 5 0 with little or no toxicity.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- the therapeutically effective dose can be estimated initially from cell culture assays.
- a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC 50 (i.e., the concentration of the test compound that achieves a half- maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans.
- compositions may comprise, for example, at least about 0.1% of an active compound.
- the an active compound may comprise between about 2% to about 75% of the weight of the unit, or between about 25% to about 60%, for example, and any range derivable therein.
- Multiple doses of the molecules of the invention are also contemplated. In some instances, when the molecules of the invention are administered with another therapeutic a sub-therapeutic dosage of either agent, or a sub-therapeutic dosage of both, is used.
- a "sub-therapeutic dose” as used herein refers to a dosage which is less than that dosage which would produce a therapeutic result in the subject if administered in the absence of the other agent. Thus, the sub-therapeutic dose of, for instance, an anti-Alzheimer's agent is one which would not produce the desired therapeutic result in the subject in the absence of the administration of the compounds of the invention.
- compositions of the invention are administered in pharmaceutically acceptable solutions, which may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, and optionally other therapeutic ingredients.
- an effective amount of the therapeutic compounds of the invention can be administered to a subject by any mode that delivers the therapeutic agent or compound to the desired surface, e.g., mucosal, systemic.
- Administering the pharmaceutical composition of the present invention may be accomplished by any means known to the skilled artisan.
- Preferred routes of administration include but are not limited to oral, parenteral, intramuscular, intranasal, sublingual, intratracheal, inhalation, ocular, vaginal, rectal and intracerebroventricular.
- the therapeutic compounds of the invention can be formulated readily by combining the active compound(s) with pharmaceutically acceptable carriers well known in the art.
- Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated.
- compositions for oral use can be obtained as solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
- suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP).
- fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol
- cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carb
- disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- the oral formulations may also be formulated in saline or buffers, i.e. EDTA for neutralizing internal acid conditions or may be administered without any carriers.
- oral dosage forms of the above component or components may be chemically modified so that oral delivery of the derivative is efficacious.
- the chemical modification contemplated is the attachment of at least one moiety to the component molecule itself, where said moiety permits (a) inhibition of proteolysis; and (b) uptake into the blood stream from the stomach or intestine.
- the increase in overall stability of the component or components and increase in circulation time in the body examples include: polyethylene glycol, copolymers of ethylene glycol and propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone and polyproline.
- the location of release may be the stomach, the small intestine (the duodenum, the jejunum, or the ileum), or the large intestine.
- One skilled in the art has available formulations which will not dissolve in the stomach, yet will release the material in the duodenum or elsewhere in the intestine.
- the release will avoid the deleterious effects of the stomach environment, either by protection of the therapeutic agent or by release of the biologically active material beyond the stomach environment, such as in the intestine.
- a coating impermeable to at least pH 5.0 is important.
- examples of the more common inert ingredients that are used as enteric coatings are cellulose acetate trimellitate (CAT), hydroxypropylmethylcellulose phthalate (HPMCP), HPMCP 50, HPMCP 55, polyvinyl acetate phthalate (PVAP), Eudragit L30D, Aquateric, cellulose acetate phthalate (CAP), Eudragit L, Eudragit S, and Shellac. These coatings may be used as mixed films.
- a coating or mixture of coatings can also be used on tablets, which are not intended for protection against the stomach. This can include sugar coatings, or coatings which make the tablet easier to swallow.
- Capsules may consist of a hard shell (such as gelatin) for delivery of dry therapeutic i.e. powder; for liquid forms, a soft gelatin shell may be used.
- the shell material of cachets could be thick starch or other edible paper. For pills, lozenges, molded tablets or tablet triturates, moist massing techniques can be used.
- the therapeutic can be included in the formulation as fine multiparticulates in the form of granules or pellets of particle size about 1 mm.
- the formulation of the material for capsule administration could also be as a powder, lightly compressed plugs or even as tablets.
- the therapeutic could be prepared by compression.
- Colorants and flavoring agents may all be included.
- the therapeutic agent may be formulated (such as by liposome or microsphere encapsulation) and then further contained within an edible product, such as a refrigerated beverage containing colorants and flavoring agents.
- these diluents could include carbohydrates, especially mannitol, a-lactose, anhydrous lactose, cellulose, sucrose, modified dextrans and starch.
- Certain inorganic salts may be also be used as fillers including calcium triphosphate, magnesium carbonate and sodium chloride.
- Some commercially available diluents are Fast-Flo, Emdex, STA-Rx 1500, Emcompress and Avicell.
- Disintegrants may be included in the formulation of the therapeutic into a solid dosage form. Materials used as disintegrates include but are not limited to starch, including the commercial disintegrant based on starch, Explotab.
- Sodium starch glycolate, Amberlite, sodium carboxymethylcellulose, ultramylopectin, sodium alginate, gelatin, orange peel, acid carboxymethyl cellulose, natural sponge and bentonite may all be used.
- Another form of the disintegrants are the insoluble cationic exchange resins.
- Powdered gums may be used as disintegrants and as binders and these can include powdered gums such as agar, Karaya or tragacanth. Alginic acid and its sodium salt are also useful as disintegrants.
- Binders may be used to hold the therapeutic agent together to form a hard tablet and include materials from natural products such as acacia, tragacanth, starch and gelatin. Others include methyl cellulose (MC), ethyl cellulose (EC) and carboxymethyl cellulose (CMC). Polyvinyl pyrrolidone (PVP) and hydroxypropylmethyl cellulose (HPMC) could both be used in alcoholic solutions to granulate the therapeutic.
- MC methyl cellulose
- EC ethyl cellulose
- CMC carboxymethyl cellulose
- PVP polyvinyl pyrrolidone
- HPMC hydroxypropylmethyl cellulose
- Lubricants may be used as a layer between the therapeutic and the die wall, and these can include but are not limited to; stearic acid including its magnesium and calcium salts, polytetrafluoroethylene (PTFE), liquid paraffin, vegetable oils and waxes. Soluble lubricants may also be used such as sodium lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol of various molecular weights, Carbowax 4000 and 6000. Glidants that might improve the flow properties of the drug during formulation and to aid rearrangement during compression might be added. The glidants may include starch, talc, pyrogenic silica and hydrated silicoaluminate.
- surfactant might be added as a wetting agent.
- Surfactants may include anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate.
- anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate.
- Cationic detergents might be used and could include benzalkonium chloride or benzethomium chloride.
- non-ionic detergents that could be included in the formulation as surfactants are lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glycerol monostearate, polysorbate 40, 60, 65 and 80, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose. These surfactants could be present in the formulation of the therapeutic agent either alone or as a mixture in different ratios.
- compositions which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
- the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- stabilizers may be added.
- Microspheres formulated for oral administration may also be used. Such microspheres have been well defined in the art. All formulations for oral administration should be in dosages suitable for such administration.
- compositions may take the form of tablets or lozenges formulated in conventional manner.
- the compounds for use according to the present invention may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide
- pulmonary delivery of the therapeutic compounds of the invention is delivered to the lungs of a mammal while inhaling and traverses across the lung epithelial lining to the blood stream.
- inhaled molecules include Adjei et al., 1990, Pharmaceutical Research, 7:565-569; Adjei et al., 1990, International Journal of Pharmaceutics, 63: 135-144 (leuprolide acetate); Braquet et al., 1989, Journal of Cardiovascular Pharmacology, 13(suppl. 5): 143-146 (endothelin-1); Hubbard et al., 1989, Annals of Internal Medicine, Vol. IJJ, pp.
- Contemplated for use in the practice of this invention are a wide range of mechanical devices designed for pulmonary delivery of therapeutic products, including but not limited to nebulizers, metered dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art.
- Ultravent nebulizer manufactured by Mallinckrodt, Inc., St. Louis, Missouri
- Acorn II nebulizer manufactured by Marquest Medical Products, Englewood, Colorado
- the Ventolin metered dose inhaler manufactured by Glaxo Inc., Research Triangle Park, North Carolina
- the Spinhaler powder inhaler manufactured by Fisons Corp., Bedford, Massachusetts.
- each formulation is specific to the type of device employed and may involve the use of an appropriate propellant material, in addition to the usual diluents, and/or carriers useful in therapy. Also, the use of liposomes, microcapsules or microspheres, inclusion complexes, or other types of carriers is contemplated.
- Chemically modified therapeutic agent may also be prepared in different formulations depending on the type of chemical modification or the type of device employed. Formulations suitable for use with a nebulizer, either jet or ultrasonic, will typically comprise therapeutic agent dissolved in water at a concentration of about 0.1 to 25 mg of biologically active compound per mL of solution.
- the formulation may also include a buffer and a simple sugar (e.g., for stabilization and regulation of osmotic pressure).
- the nebulizer formulation may also contain a surfactant, to reduce or prevent surface induced aggregation of the compound caused by atomization of the solution in forming the aerosol.
- Formulations for use with a metered-dose inhaler device will generally comprise a finely divided powder containing the therapeutic agent suspended in a propellant with the aid of a surfactant.
- the propellant may be any conventional material employed for this purpose, such as a chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane, dichlorodifiuoromethane, dichlorotetrafluoroethanol, and 1,1,1,2-tetrafluoroethane, or combinations thereof.
- Suitable surfactants include sorbitan trioleate and soya lecithin. Oleic acid may also be useful as a surfactant.
- Formulations for dispensing from a powder inhaler device will comprise a finely divided dry powder containing therapeutic agent and may also include a bulking agent, such as lactose, sorbitol, sucrose, or mannitol in amounts which facilitate dispersal of the powder from the device, e.g., 50 to 90% by weight of the formulation.
- the therapeutic agent should most advantageously be prepared in particulate form with an average particle size of less than 10 mm (or microns), most preferably 0.5 to 5 mm, for most effective delivery to the distal lung.
- Nasal delivery of a pharmaceutical composition of the present invention is also contemplated.
- Nasal delivery allows the passage of a pharmaceutical composition of the present invention to the blood stream directly after administering the therapeutic product to the nose, without the necessity for deposition of the product in the lung.
- Formulations for nasal delivery include those with dextran or cyclodextran.
- a useful device is a small, hard bottle to which a metered dose sprayer is attached.
- the metered dose is delivered by drawing the pharmaceutical composition of the present invention solution into a chamber of defined volume, which chamber has an aperture dimensioned to aerosolize and aerosol formulation by forming a spray when a liquid in the chamber is compressed.
- the chamber is compressed to administer the pharmaceutical composition of the present invention.
- the chamber is a piston arrangement.
- Such devices are commercially available.
- a plastic squeeze bottle with an aperture or opening dimensioned to aerosolize an aerosol formulation by forming a spray when squeezed is used.
- the opening is usually found in the top of the bottle, and the top is generally tapered to partially fit in the nasal passages for efficient administration of the aerosol formulation.
- the nasal inhaler will provide a metered amount of the aerosol formulation, for administration of a measured dose of the drug.
- the compounds, when it is desirable to deliver them systemically, may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
- Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
- the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- compositions for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions.
- Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
- Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
- the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
- the active compounds may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- a suitable vehicle e.g., sterile pyrogen-free water
- the compounds may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
- the compounds may also be formulated as a depot preparation.
- Such long acting formulations may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- compositions also may comprise suitable solid or gel phase carriers or excipients.
- suitable solid or gel phase carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
- Suitable liquid or solid pharmaceutical preparation forms are, for example, aqueous or saline solutions for inhalation, microencapsulated, encochleated, coated onto microscopic gold particles, contained in liposomes, nebulized, aerosols, pellets for implantation into the skin, or dried onto a sharp object to be scratched into the skin.
- the pharmaceutical compositions also include granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, drops or preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners or solubilizers are customarily used as described above.
- the pharmaceutical compositions are suitable for use in a variety of drug delivery systems. For a brief review of methods for drug delivery, see Langer, Science 249: 1527-1533, 1990, which is incorporated herein by reference.
- the therapeutic compounds of the invention and optionally other therapeutics may be administered per se (neat) or in the form of a pharmaceutically acceptable salt.
- the salts should be pharmaceutically acceptable, but non- pharmaceutical Iy acceptable salts may conveniently be used to prepare pharmaceutically acceptable salts thereof.
- Such salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulphuric, nitric, phosphoric, maleic, acetic, salicylic, p-toluene sulphonic, tartaric, citric, methane sulphonic, formic, malonic, succinic, naphthalene-2-sulphonic, and benzene sulphonic.
- such salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group.
- Suitable buffering agents include: acetic acid and a salt (1-2% w/v); citric acid and a salt (1 -3% w/v); boric acid and a salt (0.5-2.5% w/v); and phosphoric acid and a salt (0.8-2% w/v).
- Suitable preservatives include benzalkonium chloride (0.003-0.03% w/v); chlorobutanol (0.3-0.9% w/v); parabens (0.01-0.25% w/v) and thimerosal (0.004- 0.02% w/v).
- compositions of the invention contain an effective amount of a therapeutic compound of the invention optionally included in a pharmaceutically- acceptable carrier.
- pharmaceutically-acceptable carrier means one or more compatible solid or liquid filler, diluents or encapsulating substances which are suitable for administration to a human or other vertebrate animal.
- carrier denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application.
- the components of the pharmaceutical compositions also are capable of being commingled with the compounds of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficiency.
- the therapeutic agents may be delivered to the brain using a formulation capable of delivering a therapeutic agent across the blood brain barrier.
- a formulation capable of delivering therapeutics to the brain is the physiology and structure of the brain.
- the blood-brain barrier is made up of specialized capillaries lined with a single layer of endothelial cells. The region between cells is sealed with a tight junction, so the only access to the brain from the blood is through the endothelial cells.
- the barrier allows only certain substances, such as lipophilic molecules through and keeps other harmful compounds and pathogens out. Thus, lipophilic carriers are useful for delivering non- lipohilic compounds to the brain.
- DHA a fatty acid naturally occurring in the human brain has been found to be useful for delivering drugs covalently attached thereto to the brain (Such as those described in US Patent 6407137).
- US Patent 5,525,727 describes a dihydropyridine pyridinium salt carrier redox system for the specific and sustained delivery of drug species to the brain.
- US Patent 5,618,803 describes targeted drug delivery with phosphonate derivatives.
- US Patent 71 19074 describes amphiphilic prodrugs of a therapeutic compound conjugated to an PEG- oligomer/polymer for delivering the compound across the blood brain barrier.
- the compounds described herein may be modified by covalent attachment to a lipophilic carrier or co-formulation with a lipophilic carrier. Others are known to those of skill in the art.
- the therapeutic agents of the invention may be delivered with other therapeutics for enhancing memory retrieval or treating other symptoms or causes of disorders associated with the memory loss.
- environmental enrichment EE
- EE involves creating a stimulating environment around a subject.
- Other therapeutics may also be combined to treat the underlying disorder or to enhance memory recall.
- Examples of combinations of the compounds of the present invention with other drugs in either unit dose or kit form include combinations with: anti-Alzheimer's agents, beta-secretase inhibitors, gamma-secretase inhibitors, HMG-CoA reductase inhibitors, NSAID's including ibuprofen, N-methyl-D-aspartate (NMDA) receptor antagonists, such as memantine, cholinesterase inhibitors such as galantamine, rivastigmine, donepezil, and tacrine, vitamin E, CB-I receptor antagonists or CB-I receptor inverse agonists, antibiotics such as doxycycline and rifampin, anti-amyloid antibodies, or other drugs that affect receptors or enzymes that either increase the efficacy, safety, convenience, or reduce unwanted side effects or toxicity of the compounds of the present invention.
- the compounds of the invention may also be delivered in a cocktail of multiple HDAC inhibitors. The foregoing list of combinations is illustrative only
- the invention also includes articles, which refers to any one or collection of components.
- the articles are kits.
- the articles include pharmaceutical or diagnostic grade compounds of the invention in one or more containers.
- the article may include instructions or labels promoting or describing the use of the compounds of the invention.
- promoted includes all methods of doing business including methods of education, hospital and other clinical instruction, pharmaceutical industry activity including pharmaceutical sales, and any advertising or other promotional activity including written, oral and electronic communication of any form, associated with compositions of the invention in connection with treatment of cognitive disorders such as Alzheimer's disease.
- kits can define a component of promotion, and typically involve written instructions on or associated with packaging of compositions of the invention. Instructions also can include any oral or electronic instructions provided in any manner.
- the agents described herein may, in some embodiments, be assembled into pharmaceutical or diagnostic or research kits to facilitate their use in therapeutic, diagnostic or research applications.
- a kit may include one or more containers housing the components of the invention and instructions for use. Specifically, such kits may include one or more agents described herein, along with instructions describing the intended therapeutic application and the proper administration of these agents.
- agents in a kit may be in a pharmaceutical formulation and dosage suitable for a particular application and for a method of administration of the agents.
- the kit may be designed to facilitate use of the methods described herein by physicians and can take many forms.
- compositions of the kit may be provided in liquid form (e.g., in solution), or in solid form, (e.g., a dry powder).
- some of the compositions may be constitutable or otherwise processable (e.g., to an active form), for example, by the addition of a suitable solvent or other species (for example, water or a cell culture medium), which may or may not be provided with the kit.
- a suitable solvent or other species for example, water or a cell culture medium
- Instructions also can include any oral or electronic instructions provided in any manner such that a user will clearly recognize that the instructions are to be associated with the kit, for example, audiovisual (e.g., videotape, DVD, etc.), Internet, and/or web-based communications, etc.
- the written instructions may be in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which instructions can also reflects approval by the agency of manufacture, use or sale for human administration.
- the kit may contain any one or more of the components described herein in one or more containers.
- the kit may include instructions for mixing one or more components of the kit and/or isolating and mixing a sample and applying to a subject.
- the kit may include a container housing agents described herein.
- the agents may be prepared sterilely, packaged in syringe and shipped refrigerated. Alternatively it may be housed in a vial or other container for storage. A second container may have other agents prepared sterilely.
- the kit may include the active agents premixed and shipped in a syringe, vial, tube, or other container.
- the kit may have a variety of forms, such as a blister pouch, a shrink wrapped pouch, a vacuum sealable pouch, a sealable thermoformed tray, or a similar pouch or tray form, with the accessories loosely packed within the pouch, one or more tubes, containers, a box or a bag.
- the kit may be sterilized after the accessories are added, thereby allowing the individual accessories in the container to be otherwise unwrapped.
- the kits can be sterilized using any appropriate sterilization techniques, such as radiation sterilization, heat sterilization, or other sterilization methods known in the art.
- the kit may also include other components, depending on the specific application, for example, containers, cell media, salts, buffers, reagents, syringes, needles, a fabric, such as gauze, for applying or removing a disinfecting agent, disposable gloves, a support for the agents prior to administration etc.
- other components for example, containers, cell media, salts, buffers, reagents, syringes, needles, a fabric, such as gauze, for applying or removing a disinfecting agent, disposable gloves, a support for the agents prior to administration etc.
- compositions of the kit may be provided as any suitable form, for example, as liquid solutions or as dried powders.
- the powder When the composition provided is a dry powder, the powder may be reconstituted by the addition of a suitable solvent, which may also be provided.
- the liquid form may be concentrated or ready to use.
- the solvent will depend on the compound and the mode of use or administration. Suitable solvents for drug compositions are well known and are available in the literature. The solvent will depend on the compound and the mode of use or administration.
- kits in one set of embodiments, may comprise a carrier means being compartmentalized to receive in close confinement one or more container means such as vials, tubes, and the like, each of the container means comprising one of the separate elements to be used in the method.
- container means such as vials, tubes, and the like
- each of the container means comprising one of the separate elements to be used in the method.
- one of the containers may comprise a positive control for an assay.
- the kit may include containers for other components, for example, buffers useful in the assay.
- the present invention also encompasses a finished packaged and labeled pharmaceutical product.
- This article of manufacture includes the appropriate unit dosage form in an appropriate vessel or container such as a glass vial or other container that is hermetically sealed.
- the active ingredient is sterile and suitable for administration as a particulate free solution.
- the invention encompasses both parenteral solutions and lyophilized powders, each being sterile, and the latter being suitable for reconstitution prior to injection.
- the unit dosage form may be a solid suitable for oral, transdermal, topical or mucosal delivery.
- the unit dosage form is suitable for intravenous, intramuscular or subcutaneous delivery.
- the invention encompasses solutions, preferably sterile, suitable for each delivery route.
- compositions of the invention are stored in containers with biocompatible detergents, including but not limited to, lecithin, taurocholic acid, and cholesterol; or with other proteins, including but not limited to, gamma globulins and serum albumins. More preferably, compositions of the invention are stored with human serum albumins for human uses, and stored with bovine serum albumins for veterinary uses.
- the packaging material and container are designed to protect the stability of the product during storage and shipment.
- the products of the invention include instructions for use or other informational material that advise the physician, technician or patient on how to appropriately prevent or treat the disease or disorder in question.
- the article of manufacture includes instruction means indicating or suggesting a dosing regimen including, but not limited to, actual doses, monitoring procedures and other monitoring information.
- the invention provides an article of manufacture comprising packaging material, such as a box, bottle, tube, vial, container, sprayer, insufflator, intravenous (i.v.) bag, envelope and the like; and at least one unit dosage form of a pharmaceutical agent contained within said packaging material.
- the invention also provides an article of manufacture comprising packaging material, such as a box, bottle, tube, vial, container, sprayer, insufflator, intravenous (i.v.) bag, envelope and the like; and at least one unit dosage form of each pharmaceutical agent contained within said packaging material.
- packaging material such as a box, bottle, tube, vial, container, sprayer, insufflator, intravenous (i.v.) bag, envelope and the like; and at least one unit dosage form of each pharmaceutical agent contained within said packaging material.
- the invention further provides an article of manufacture comprising a needle or syringe, preferably packaged in sterile form, for injection of the formulation, and/or a packaged alcohol pad.
- an article of manufacture comprises packaging material and a pharmaceutical agent and instructions contained within said packaging material, wherein said pharmaceutical agent is a HDAC2 inhibitor and a pharmaceutically acceptable carrier, and said instructions indicate a dosing regimen for preventing, treating or managing a subject with cognitive disorders such as Alzheimer's disease.
- Therapeutic Monitoring The adequacy of the treatment parameters chosen, e.g. dose, schedule, adjuvant choice and the like, is determined by conventional methods for monitoring memory.
- the clinical condition of the patient can be monitored for the desired effect, e.g. increases in cognitive function. If inadequate effect is achieved then the patient can be boosted with further treatment and the treatment parameters can be modified, such as by increasing the amount of the composition of the invention and/or other active agent, or varying the route of administration.
- mice Up to four mice were continuously housed in a cage that contained two wheels for voluntary running and a variety of toys (obtained form from Petco) to create tunnels, and climbing devices. Food and water was ad libitum. The food was hidden within the bedding. Toys and running wheels were changed on a daily basis. Cannulation and injection: Microcannula were inserted into the lateral brain ventricles. Sodiumbutyrate (Sigma; St. Louis, MO) was dissolved in artificial cerebrospinal fluid (aCSF). A stock solution of TSA (Sigma) was dissolved in DMSO and diluted with aCSF before injection.
- aCSF artificial cerebrospinal fluid
- HDAC overexpression animals The mouse HDAC l or HDAC2 coding sequence was placed into exon 1 of the Tau gene, in-frame with the endogenous initiation codon, thereby creating a fusion protein that contains the first 31 amino acids of Tau.
- HDAC2 KO was produced in the laboratory of R.A.D. and engineered to contain loxP recombination sites such that Cre-mediated recombination deletes exons 5 and 6 which encodes the key catalytic core of the HDAC protein.
- Chemical delivery Sodium butyrate (sigma) was dissolved in saline.
- HDAC inhibitors were dissolved in DMSO in 50mg/ml and diluted with saline immediate before injection (l OOul-150ul, i.p.).
- Immunoblotting and staining Lysates for immunoblotting were prepared as described herein (see also Fischer, A. et al. Recovery of learning and memory is associated with chromatin remodeling. Nature 447 (7141), 178-182 (2007).). Briefly, to isolate histones, brain tissue was homogenized in TX-buffer (50 mM Tris HCl, 150 mM NACl, 2 mM EDTA, 1% Triton- 100) and incubated at 4 0 C for 15 min before centrifugation at 2,000 r.p.m. (40Og) for 10 min.
- TX-buffer 50 mM Tris HCl, 150 mM NACl, 2 mM EDTA, 1% Triton- 100
- HDACl overexpression mice The -1200 nt-long mouse HDACl cDNA was amplified from a brain cDNA library and confirmed by sequencing. The cDNA was then cloned upstream of the polyadenylation (pA) signal of pC8N2 with a Spel blunt ligation, subsequently HDACl-pA was cloned into pBSK (Stratagene). A pGKneoLoxP sequence was directionally inserted into the Xho ⁇ -Kpn ⁇ site downstream of the HDAC 1-pA in pBSK.
- pA polyadenylation
- the HDACl-pA-neo was released with Xmal-Acc65 and cloned in frame into exon 1 of the Tau gene.
- the Tau targeting arms were taken from pTauKR and modified by insertion of a Xmal and Bs ⁇ Wl linker in the unique Ncol site.
- the resulting targeting vector (pTHl) containing the in frame fusion of HDACl coding sequence with exon 1 of Tau was confirmed by sequencing. 3-6-month- old mice were used for the behavior test and further analysis.
- HDAC2 overexpression mice The mouse HDAC2 cD ⁇ A was obtained using RT PCR from mouse brain tissue. It was sequenced and subcloned into the Xhol-EcoRl site of the Topo-TA vector (Invitrogen). The pTHl targeting vector (described above) was cut open with Smal-Sall to release HDACl . The HDAC2 cD ⁇ A was cut out from Topo-TA with an EcoRI-Xhol and cloned into the Smal-Sall site of pTHl, to create the pTH2 targeting vector. The in frame fusion of HDAC2 to exon 1 of Tau was verified by sequencing of pTH2.
- the targeting vectors pTHl and pTH2 were linearized with Sac ⁇ and electroporated into V6.5 (129XC57BL/6) Fl embryonic stem (ES) cell line.
- V6.5 129XC57BL/6) Fl embryonic stem (ES) cell line.
- ES Fl embryonic stem
- Two clones were used to generate chimeras by injections into (DBA/2XC57BL/6) Fl blastocysts.
- Chimeras were mated to C57BL/6 females and offspring was analyzed for germline transmission.
- the heterozygous knock-in strains were maintained in a mixed background and were mated to obtain homozygous animals. 3-6-month-old mice were used for the behavior test and further analysis.
- Hdac2 KO mice The Hdac2 floxed allele was generated by flanking exon 5 and exon 6 with lox? recombination sites, assuring the deletion of the HDAC-catalytic core of the protein after Cre-recombinase mediated deletion.
- Hdac2 L a floxed allele of Hdac 2
- FVB cowpoxed allele of Hdac 2
- Hd ⁇ c2-def ⁇ cient mice but these mice were born with a 2-fold lower frequency than expected from a normal Mendelian ratio (9 Hdac2 '/' mice out of 79 littermates, versus 20 out of 79 expected;. Although Hdac2 '/' mice are viable and are capable of producing offspring their fertility is compromised (data not shown). Hdac2 '/' mice (males and females) were approximately 25% smaller compared to wild-type and heterozygote littermates (data not shown). The animals used for behavior tests are in FVBxC57/BL6 background and mated to each other to obtain homozygous animals. 3-6-month-old mice were used for the behavior test and further analysis. There was no difference in behavior tests between males and females.
- Training consists of a 3 min exposure of mice to the conditioning box (context) followed by a foot shock (2 sec, 0.5/0.8/1.0 mA, constant current).
- the memory test was performed 24 hr later by re-exposing the mice for 3 min into the conditioning context. Freezing, defined as a lack of movement except for heart beat and respiration associated with a crouching posture, was recorded every 10 sec by two trained observers (one was unaware of the experimental conditions) during 3 min (a total of 18 sampling intervals). The number of observations indicating freezing obtained as a mean from both observers was expressed as a percentage of the total number of observations.
- the memory test was performed 3 hrs after the foot shock training.
- Tone-dependent fear conditioning Training consisted of a 3 min exposure of mice to the conditioning box (context), followed by a tone [30 sec, 20 kHz, 75 dB sound pressure level (SPL)] and a foot shock (2 sec, 0.8 tnA, constant current). The memory test was performed 24 hr later by exposing the mice for 3 min to a novel context followed by an additional 3 min exposure to a tone (10 kHz, 75 dB SPL). Freezing was recorded every 10 sec by two nonbiased observers as described above.
- mice were forced either left or right by the presence of a plastic block, according to a pseudorandom sequence (with equal numbers of left and right turns per session, and with no more than two consecutive turns in the same direction).
- a reward consisting of 0.07 ml of sweetened, condensed milk (diluted 50/50 with water) was available in the food well at the end of the arm.
- the block was then removed, and the mouse was placed, facing the experimenter, at the end of the start arm and allowed a free choice of either arm.
- the time interval between the sample run and the choice run was approximately 15 s.
- the animal was rewarded for choosing the previously unvisited arm (that is, for alternating).
- Mice were run one trial at a time with an inter-trial interval (ITI) of approximately 10 min. Each daily session consisted of 4 trials, and mice received 24 trials in total.
- ITI inter-trial interval
- SAHA Suberoylanilide hydroxamic acid
- Tomato expressing HSV (0.5 ⁇ l, gift from Rachael Neve) was stereo-injected into both sides of area CAl or dentate gyrus with 0.05 ⁇ l/min rate. Mice were sacrificed 48 hrs after injection. Brains were fixed with 4% PFA and sectioned with vibratome (50 ⁇ m, Leica). Hippocampal slices were scanned with a confocal microscope. Obtained image stacks were reconstructed and analyzed using image J.
- Immunohistochemistry Immunohistochemical analysis was performed as described before (Guan, J.S., et al., Cell, 2005. 122(4): p. 619-31.)- Antibodies were used in a 1 : 1000 concentration.
- Anti-HDACl, and anti-HDAC2 antibodies were purchased from Abeam.
- Anti-Ac-lysine, anti-Ac-H4K5, anit-Ac-H4K12, anti-Ac-H3K16, anti- CREB, anti-AKT and anti-CaMKII ⁇ antibodies were purchased from Cell Signaling.
- Anti-Ac- ⁇ -tubulin (K40), anti-actin and anti-synaptophysin (SVP-38) antibodies were purchased from Sigma.
- Anti-NR2A and anti-NR2B were purchased from BD Biosciences. Anti- ⁇ -catenin, anti-EGRl, anti-c-FOS, anti-Brnl, anti-TLE4, anti-CDP, anti-ER81 and anti-GAPDH antibodies were purchased from Santa Cruz. Anti-NeuN antibody was purchased from Chemicon. Confocal images (1 ⁇ m) were scanned and subjected to three-dimensional reconstruction. LSMetalO software (Zeiss) was used to calculate the mean synaptophysin intensity. Brain sections with the strongest intensity were scanned first. All other images included in the analysis were scanned using the same settings. Staining was quantified using LSMetalO software (Zeiss).
- the hippocampus and forebrain were collected and lysed in RIPA buffer. The lysates were incubated for 15 min on ice and centrifuged for 15 min at 15,000 X g at 4°C. The supernatant was collected as cytosolic protein extract. The lysates were subjected to 10% SDS-PAGE followed by immunoblotting.
- Hippocampus samples were collected and homogenized in 400 ⁇ l TX-buffer (5OmM Tris-HCl , pH8.5, 5mM sodium butyrate). The pellets were resuspended in 0.2M HC1/TX buffer and incubated on ice for 30 mins. Samples were spun down at 14000 rpm, the histone containing supematants were subjected to western analysis.
- TX-buffer 5OmM Tris-HCl , pH8.5, 5mM sodium butyrate
- HDAC2OE, HDAC2KO or their littermates were killed by cervical dislocation, and hippocampi were rapidly dissected in iced oxygenated artificial CSF (ACSF).
- Transverse hippocampal slices, 400 ⁇ m thick were placed in a chamber and continuously perfused with oxygenated ACSF.
- a bipolar stimulating electrodes (0.002-inch-diameter nichrome wire; A-M Systems) placed in the stratum radiatum was used to elicit action potentials in CA3 axons.
- An ACSF-filled glass microelectrode with a resistance between 0.5 and 3 M ⁇ was placed in the stratum radiatum region of CAl and was used to record the field excitatory post-synaptic potentials (fEPSP).
- LTP was induced by applying one train of stimuli at 100 Hz for Is.
- LTP was induced by applying two trains of stimuli at 100Hz for Is, with an interval of 20s.
- E17 Embryonic cortici
- EGRl-GFP BAC transgenic mice Genesat Project
- Cortical neurons were plated at a density of 10,000 cells per well in black/clear bottom plates coated with poly- D-lysine (Costar) in neurobasal medium (1.6% B27, 2% glutamax, 1% pen/strep and 5% heat inactivated fetal calf serum) and in neurobasal medium without serum 24 hrs later. Under these culture conditions, the percentage of glia was estimated to be in the range of 5-25.
- HDAC inhibitors or DMSO control triplicates or quadruplicates
- BDNF, KCl or forskolin were added to the cultures on day 7 for 8hrs.
- Cell were fixed in 4% PF A/4% sucrose in PBS. Fixative was washed away with PBS (3 wash cycles) and processed for EGRl -GFPimaging. Cells ( 3,000 - 5,000 per well) were imaged and analyzed with 5X objective using the Cellomics ArrayScan Image system. The built-in TargetActivation algorithm was optimized to measure average EGRl-GFP expression per cell (mean Fluorescence intensity per cell per well), using the Hoechst dye to mark cells. The data was normalized to control (medium addition).
- cells were processed for antibody staining: cells were permeabilized with 0.25% TritonXIOO (10-15min). Triton was washed away by 3 PBS wash cycles, cells were blocked in PBS containing 10% goat or horse serum (lhr, 37°C). Cells were exposed to anti-acetyl-Lysine -histone H3 or H4 antibody. Then washed 5 times with PBS followed by secondary antibody conjugated to Alexa594, and Hoechst (l hr, RT). Secondary antibody was washed 5 times with PBS, and assayed on Cellomics ArrayScan Image system.
- ChIP Chromatin immunoprecipitation
- the resulting whole-cell extract was incubated overnight at 4°C with 100 ⁇ l of Dynal Protein G magnetic beads that had been preincubated with 10 ⁇ g of the appropriate antibody. Beads were washed five times with RIPA buffer and one time with TE containing 50 mM NaCl. Bound complexes were eluted from the beads by heating at 65°C with occasional vortexing and crosslinking was reversed by overnight incubation at 65°C. Whole-cell extract DNA (reserved from the sonication step) was also treated for crosslink reversal.
- Immunoprecipitated DNA and whole-cell extract DNA were then purified by treatment with RNaseA, proteinase K, and multiple phenol:chloroform:isoamyl alcohol extractions. Purified DNA samples were normalized and subjected to PCR analysis. Antibodies used for pull downs were: anti-HDAC l (#31263),anti-HDAC2(# 12169) from Abeam; anti- AcH4 (#06-866), anti-AcH3(# 06-599) from Upstate.
- Real-time PCR was carried out with SYBR-Green-based reagents (Invitrogen, express SYBR GreenER) using a CFX96 real-time PCR Detection system (BioRad). The relative quantities of immunoprecipitated DNA fragments were calculated using the comparative CT method. Results were compared to a standard curve generated by serial dilutions of input DNA. Data were derived from three independent amplifications. Error bars represent standard deviations. Primer sequences used for PCR:
- BDNF PI 5'-TGATCATCACTCACGACCACG-S' (SEQ ID NO: 3) 5'- C AGCCTCTCTG AGCCAGTTACG-S' (SEQ ID NO: 4)
- BDNF PII 5'-TGAGGATAGTGGTGGAGTTG-S ' (SEQ ID NO: 5) 5'-
- BDNF PIV 5'-GCGCGGAATTCTGATTCTGGTAAT-S' (SEQ ID NO: 7) 5'GAGAGGGCTCCACGCTGCCTTGACG-S' (SEQ ID NO: 8)
- CREB 5'- CTACACCAGCTTCCCCGGT-3' (SEQ ID NO: 9) 5'-
- PKM zeta (lOObp upstream of the PKMzeta mRNA initiation site [15], which contains a cAMP response element (CRE) consensus sequence): 5'-TGTTGAGTCTGGGCCCTC-3' (SEQ ID NO: 1 1) 5 '-CCTGGCCTCCGGACC-S ' (SEQ ID NO: 12)
- CBP Creb binding protein
- Neurexin I 5'- CAGGGCCTTTGTCCTGAATA-3' (SEQ ID NO: 15) 5'-
- ATF4 5 '-GTGATAACCTGGCAGCTTCG-S ' (SEQ ID NO: 21) 5'- GGGGTAACTGTGGCGTTAGA-3 ' (SEQ ID NO: 22)
- CaMKIIA 5'- GACCTGGATGCTGACGAAG-3' (SEQ ID NO: 23) 5'-
- Agrin 5 '-TTGTAACCAACAGGGGTTGC-S ' (SEQ ID NO: 29) 5'-
- EGR-2 5 '-GGCTGCAAATCGTTCCTG-S ' (SEQ ID NO: 31) 5'- TCGGAGT ATTTATGGGCAGGT-3' (SEQ ID NO: 32)
- CDK5 5 '-CGCAGCCTGTTGGACTTTGT-S ' (SEQ ID NO: 43) 3'-
- SHANK3 5'-TTTTCCAGGTCCCAGTGGTG-S ' (SEQ ID NO: 45) 5'- CCTGCCCACAGTGTCACTCC-3 ' (SEQ ID NO: 46)
- CPG 15 5 '-GCGAGATTTCGTTGAGATCG-S ' (SEQ ID NO: 59) 5 '- GGGATGACACGG ATTGATTTT-3 ' (SEQ ID NO: 60)
- SNK 5 '-TTTCCCACGTCCAAAGTCAG-S ' (SEQ ID NO: 61) 5 '- GCAGCGAAGCTTTAAATACGC-3' (SEQ ID NO: 62)
- NR2A 5 '-TCGGCTTGGACTGATACGTG-S ' (SEQ ID NO: 63) 5'- AGGATAGACTGCCCCTGCAC-3' (SEQ ID NO: 64)
- NR2B 5 '-CCTTAGGAAGGGGACGCTTT-S ' (SEQ ID NO: 65) 5'- GGC AATT AAGGGTTGGGTTC-3' (SEQ ID NO: 66)
- TUBULIN 5 '-TAGAACCTTCCTGCGGTCGT-S ' (SEQ
- Example 1 SAHA was administered daily by intraperitoneal (i.p.) injection at 25mg/kg for 10 days prior to contextual fear conditioning training and memory test.
- HDAC20E mice after SAHA treatment were comparable to those of the control mice treated with SAHA, despite the fact that saline treated HDAC2OE mice exhibited lower freezing behavior.
- SAHA treatment completely abrogated the decreased dendritic spine and synapses phenotype in HDAC2OE mice (Fig I B, C).
- HDAC2 is the major, if not the only target of SAHA in eliciting memory enhancement.
- SAHA was initially reported to be a pan-HDACi, although recent studies using recombinant HDACs and in vitro deacetylase assays with appropriate class-specific substrates have revealed that SAHA is a more potent inhibitor of class I HDACs and HDAC6, with very weak to no inhibition of class Ha HDACs, such as HDAC4, 5, and 7.
- SB does not inhibit the activity of HDAC6 in vitro, to directly address the potential importance of this class Hb HDAC, we tested whether selectively inhibiting HDAC6 has any effects on memory formation using the HDACi WT-161 (Fig 2A,B).
- ⁇ - Tubulin(K40) deacetylation is a known non-histone substrate of HDAC6 that served as specificity control in these experiments. While WT-161 increased ⁇ -tubulin(K40) levels in hippocampal pyramidal neurons(Fig 2C), there was no correlated increase in memory formation (Fig 2D). This result, and the observed cellular selectivity of SB and WT-161, suggests that HDAC6 inhibition by SAHA might not be involved in HDACi induced memory enhancement. In agreement with these, proteome-wide studies of a SAHA- based affinity probe identified HDAC l and HDAC2 as the main cellular targets. Thus, class I HDACs, especially HDACl and HDAC2, might be the potential target for HDACi induced memory enhancement.
- HDACl and HDAC2 were over-expressed in neurons.
- the mouse HDACl or HDAC2 coding sequence was placed into exon 1 of the Tau gene, in-frame with the endogenous initiation codon, thereby creating a fusion protein that contains the first 31 amino acids of Tau.
- homozygous animals mutant for Tau were shown to be phenotypically indistinguishable from wild-type littermates in memory tests.
- a 2-3 fold increase in HDACl or HDAC2 protein expression in brain of homozygous animals as compared to WT mice was observed in the hippocampus and other areas of the brain (Fig. 3).
- HDAClOE homozygous HDACl
- HDAC2OE HDAC2 overexpression mice
- acetylated H4K12, H4K5 but not H3K14 was decreased in brains of HDAC2OE mice (data not shown).
- acetylated ⁇ - tubulin(K40) level did not change in the HDAClOE or HDAC2OE mice.
- WT wildtype
- HDAC2 deficient mice HDAC2KO
- mice carrying a floxed Hdac2 allele HDAC2 deficient mice
- Germ-line deletion of Hdac2 resulted in viable and fertile Hdac2 +/ ⁇ mice with no obvious histological abnormalities up to a year of age (Fig. 5).
- Crossing Hdac2 +/ ⁇ mice gave rise to viable Hifac2-deficient mice, in which ⁇ DAC2 expression was abolished in the brain.
- HDAC2 KO mice showed enhanced fear conditioning.
- HDAC2 does not lead to detectable changes in the anatomy or cell positioning in the brain.
- H4K5, H4K12 and H2B acetylation was significantly increased in the hippocampus of HDAC2KO mice.
- overall acetylation of lysine residues in histone preparation was slightly decreased as revealed by western blot analysis using the acetylated-lysine antibody. This might be the consequence of a compensatory increase of HDACl in HDAC2KO mice (Fig. 5D).
- HDAC2 loss of function enhanced associative learning.
- Example 2 In vitro assays were used to test the protective effects of HDAC overexpression on p25 induced toxicity. Neurons are dissociated from El 5.5 cortex and hippocampus. They were transfected with plasmids encoding p25-GFP and Flag- HDACs at DIV4. 24hrs after transfection, neurons were fixed and processed for IHC. HDACl, 5,6, 7 and 10 showed protection (Fig 7).
- HDAC HDAC2
- HDAC 1 and HDAC2 were reported to form functional hetero-dimmers (Grozinger, C. M. & Schreiber, S. L. Chem Biol 9 (1), 3-16 (2002)).
- HDAC2 is a suitable target for memory enhancement.
- neuronal HDAC2 and HDACl might form distinct complexes with transcriptional co-repressors and therefore are enriched in different regions of the chromatin.
- HDAC2 may differentially target additional non-histone proteins, which may be involved in memory formation.
- Other possibilities, such as difference in posttranscriptional modification might also contribute to the biochemical/functional dissociation between HDAC l and HDAC2.
- HDAC l deficiency in mice is detrimental, resulting in embryonic lethality.
- HDACl loss of function in neurons causes DNA damage and cell death.
- HDAC2 deficient mice are viable and exhibit enhanced memory formation.
- Bottai, D., et al. Synaptic activity-induced conversion ofintronic to exonic sequence in Homer 1 immediate early gene expression. J Neurosci, 2002. 22(1): p. 167-75.
- Example 3 In vitro enzymatic inhibitions assay data
- BRD-9853 showed minimal activity in this cell line.
- BRD-4097 was the negative control. This is a benzamide with minimal HDAC inhibitory activity.
- FIG 12 demonstrates western blots of primary striatal cells isolated from mouse brain that have been treated with HDAC inhibitors. Two sets of data with 3 independent samples/set are presented. Histograms representing the quantification of westerns are also shown. Relative to DMSO controls, BRD-6929 has a significant effect on the acetylation levels of histone locus H4K12. BRD-6929 treatment results in a 5-10 fold increase at 1 and 10 uM. BRD-6929 is an HDAC 1,2 selective compound, and has 20Ox selectivity for HDAC 1,2 vs. HDAC3. This demonstrates that an HDAC 1,2 selective compound can effectively increase acetylation marks associated with HDAC2 inhibition and memory, H4K12.
- HDAC 1 ,2 selective compound is as effective at increasing acetylation as an HDAC 1,2,3 inhibitor and a pan inhibitor (i.e. SAHA). Inhibiting HDAC 1,2 is sufficient to effect increased acetylation at this histone locus.
- Figure 13 shows histograms representing the quantification of western gel analysis examining additional acetylation marks in primary striatal cells.
- Four compounds were tested including CI-994 (BRD-3696) and SAHA.
- BRD-6929 and BRD-5298 have significantly increased tetra-acetylated H4. Both compounds also show a trend toward increasing tetra-acetylated H2B.
- BRD-6929 and BRD-5298 treatment results in a 2-5 fold increase in both marks at 1 and 10 uM.
- This data demonstrates that HDAC 1,2 specific compounds (BRD-6929, 5298) are effective in increasing a specific acetylation associated with the inhibition of HDAC2 and learning and memory.
- Example 6 In vitro data with BRD-6929 in neuronal cell lines (Immunofluorescent analysis). Materials and Methods:
- a multichannel pipet or use liquid handling system e.g. Combi, standard tubing; slow speed
- 75 ul formaldehyde 4 % in PBS
- BRD-6929 at 1 and 10 uM does not cause an increase or decrease in overall cell number after 6 h incubation in brain region specific primary cultures (cortex and striatum).
- BRD-6929 at 10 uM causes an increase in H4K12 acetylation after 6 h incubation in brain region specific primary cultures (striatum) ( Figure 14).
- BRD-6929 and BRD-5298 (HDAC 1,2 selective inhibitors) at 1 and 10 uM cause a significant increase in H2B acetylation after 6 h incubation in primary neuronal cell cultures ( Figures 15, 16).
- HDAC 1,2 selective compounds are effective in increasing the acetylation at the specific histone locus H2B. Increased acetylation of this histone locus is associated with the inhibition or modulation of HDAC2 and learning and memory. To our knowledge there are no reports of compounds with this HDAC inhibitory selectivity eliciting these specific marks in this specific cell type.
- Example 7 Concentration-time curve of BRD-6929 in plasma and brain
- Figure 17 represents a summary of the pharmacokinetic data after a single dose of 45 mg/kg BRD-6929 administered systemically via intraperitoneal injection.
- concentration time curves for BRD-6929 in the plasma and brain of C-57 mice from 5 min to 24 h are shown.
- This data demonstrates that BRD-6929 crosses the blood-brain barrier and achieves concentrations in excess of its HDAC 1 and 2 IC50 in whole brain.
- the brain Cmax (0.83 uM) and the AUC (3.9 uM) levels are well above effective in vitro concentrations necessary for enzymatic inhibition.
- Example 8 Increase in acetylation marks in brain specific regions related to learning and memory after acute dosing in mice.
- frozen brain tissue a. On ice, thaw frozen tissue and immediately homogenize carefully in 25OuL of ice-cold Suspension Buffer. (10OuL was used for tissue approx. 2-3mm3; adjust as needed)
- Suspension Buffer 0.1 M NaCl , O.OIM TrisCl (pH 7.6) ,0.00 I M EDTA (pH 8.0) (buffer to this point can be prepared ahead, room temp, storage) Just before use, add: I x phosphatase/protease inhibitor cocktail (ex. ThermoFisher "HALT,"cat# 78440)
- BRD-6929 causes a significant increase in the levels of tetra-acetylated H2B in the cortex of mice ( Figure 19). This demonstrates that BRD-6929 is a functional inhibitor of HDACs in the cortex after a single dose given systemically. BRD-6929 causes a 1.5-2 fold increase in the acetylation levels for H2BK5 ( Figure 20). This acetylation mark has been associated with increased learning and memory.
- BRD-6929 an HDAC 1,2 selective inhibitor, has entered the brain, and the nucleus of cells located in specific brain regions associated with learning and memory.
- BRD-6929 causes an increase in specific acetylation marks which have also been associated with learning and memory effects.
- Example 9 Increase in acetylation marks in whole brain after chronic administration of BRD-6929.
- Example 10 Behavioral data in mice: phenotypes that correspond to improved memory and cognition C57/BL6 WT mice were injected with vehicle or BRD-6929 for 10 days. On day
- mice were trained in contextual fear conditioning paradigm (Training consisted of a 3 min exposure of mice to the conditioning box (context, TSE) followed by a foot shock (2 sec, 0.8 mA, constant current). One hour after training, mice were injected with BRD- 6929 or vehicle. On day 12, mice were returned to the training box and the freezing behavior were monitored and recorded.
- Context context
- foot shock 2 sec, 0.8 mA, constant current
- the aqueous layer was adjusted to pH ⁇ 3 with a IM aqueous solution of HCl.
- the product was extracted with ethyl acetate.
- the combined organic layer were filtered, dried over sodium sulfate and concentrated in vacuo to give the desired product as a yellow solid (10.3 g, 89% yield).
- Nl-(2-amino-5-(thiophen-2-yl)phenyl)-N4-(2-(4-methylpiperazin-l- yl)ethyl)terephthalamide (BRD-5298) can be prepared by substituting pyridin-3- ylboronic acid with thiophen-2-ylboronic acid.
- ESI+ MS m/z (rel intensity) 464 (98.27, M+H).
- Nl-(2-amino-5-(thiophen-2-yl)phenyl)-N4-(2-(pyridin-4-yl)ethyl)terephthalamide (BRD-6597) can be prepared by substituting 2-(4-methylpiperazin-l-yl)ethanamine with 2-(pyridin-4-yl)ethanamine.
- ESI+ MS m/z (rel intensity) 443 (97.68, M+H).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Storage Device Security (AREA)
- Techniques For Improving Reliability Of Storages (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011539506A JP2012510512A (en) | 2008-12-03 | 2009-12-02 | Inhibition of HDAC2 to promote memory |
CA2745073A CA2745073A1 (en) | 2008-12-03 | 2009-12-02 | Inhibition of hdac2 to promote memory |
US13/132,179 US20120101147A1 (en) | 2008-12-03 | 2009-12-02 | Inhibition of hdac2 to promote memory |
AU2009322958A AU2009322958B2 (en) | 2008-12-03 | 2009-12-02 | Inhibition of HDAC2 to promote memory |
EP09830725A EP2367599A4 (en) | 2008-12-03 | 2009-12-02 | Inhibition of hdac2 to promote memory |
NZ593447A NZ593447A (en) | 2008-12-03 | 2009-12-02 | Inhibition of hdac2 to promote memory |
CN2009801532239A CN102271763A (en) | 2008-12-03 | 2009-12-02 | Inhibition of hdac2 to promote memory |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11969808P | 2008-12-03 | 2008-12-03 | |
US61/119,698 | 2008-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010065117A1 true WO2010065117A1 (en) | 2010-06-10 |
Family
ID=42233521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/006355 WO2010065117A1 (en) | 2008-12-03 | 2009-12-02 | Inhibition of hdac2 to promote memory |
Country Status (8)
Country | Link |
---|---|
US (1) | US20120101147A1 (en) |
EP (1) | EP2367599A4 (en) |
JP (1) | JP2012510512A (en) |
CN (1) | CN102271763A (en) |
AU (1) | AU2009322958B2 (en) |
CA (1) | CA2745073A1 (en) |
NZ (1) | NZ593447A (en) |
WO (1) | WO2010065117A1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102477001A (en) * | 2010-11-29 | 2012-05-30 | 江苏先声药物研究有限公司 | Benzamide histone deacetylase inhibitor |
EP2493298A1 (en) * | 2009-10-30 | 2012-09-05 | Massachusetts Institute of Technology | The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders |
WO2013017542A1 (en) * | 2011-07-29 | 2013-02-07 | Georg-August-Universität Göttingen | Method for preventing or treating memory impairment and pharmaceutical compositions useful therefor |
EP2598133A2 (en) * | 2010-07-30 | 2013-06-05 | The Regents of The University of California | Method and therapeutic for the treatment and regulation of memory formation |
JP2014523857A (en) * | 2011-04-28 | 2014-09-18 | ザ ブロード インスティテュート, インコーポレイテッド | Histone deacetylase inhibitor |
EP2801569A1 (en) | 2013-05-09 | 2014-11-12 | Ikerchem, S.L. | Histone deacetylase inhibitors based on derivatives of tricyclic polyhydroacridine and analogs possessing fused saturated five- and seven-membered rings |
US9115053B2 (en) | 2011-07-22 | 2015-08-25 | Massachusetts Institute Of Technology | Activators of class I histone deacetlyases (HDACS) and uses thereof |
US9790184B2 (en) | 2012-07-27 | 2017-10-17 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
US9914717B2 (en) | 2012-12-20 | 2018-03-13 | The Broad Institute, Inc. | Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors |
WO2019014418A1 (en) * | 2017-07-13 | 2019-01-17 | Massachusetts Institute Of Technology | Targeting the hdac2-sp3 complex to enhance synaptic function |
AU2018203354B2 (en) * | 2011-12-21 | 2019-12-05 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
WO2021117759A1 (en) | 2019-12-10 | 2021-06-17 | 塩野義製薬株式会社 | Histone deacetylase inhibitor having nitrogen-containing aromatic heterocyclic group |
EP3982968A4 (en) * | 2019-06-13 | 2023-07-05 | Dana-Farber Cancer Institute, Inc. | Hdac3 catalytic inhibitor development and uses thereof |
US12043607B2 (en) | 2021-12-03 | 2024-07-23 | Tango Therapeutics, Inc. | HDAC inhibitors and therapeutic use thereof |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8263547B2 (en) | 2008-05-28 | 2012-09-11 | Massachusetts Institute Of Technology | DISC-1 pathway activators in the control of neurogenesis |
WO2014018913A2 (en) * | 2012-07-27 | 2014-01-30 | University Of Connecticut | Santacruzamate a compositions and analogs and methods of use |
WO2014046871A1 (en) * | 2012-09-04 | 2014-03-27 | Massachusetts Institute Of Technology | The use of gene expression profiling as a biomarker for assessing the efficacy of hdac inhibitor treatment in neurodegenerative conditions |
CN104884426A (en) | 2012-12-28 | 2015-09-02 | 日本脏器制药株式会社 | Cinnamic acid amide derivative |
KR101486248B1 (en) * | 2013-04-29 | 2015-01-27 | 숙명여자대학교산학협력단 | Pharmaceutical composition containing DNA methylation inhibitors for treating autosomal dominant polycystic kidney disease |
CA2931345A1 (en) * | 2013-11-24 | 2015-05-28 | Taipei Medical University | Use of indolyl and idolinyl hydroxamates for treating neurodegenerative disorders or cognitive deficits |
EP3122181A4 (en) * | 2014-03-26 | 2018-04-25 | The Brigham and Women's Hospital, Inc. | Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells |
WO2016134271A1 (en) | 2015-02-19 | 2016-08-25 | Massachusetts Institute Of Technology | Systems and methods for selective memory enhancement and/or disruption |
KR20180014432A (en) * | 2015-06-08 | 2018-02-08 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Use of H3K9me3 Regulation to Enhance Cognitive Function |
US11149062B2 (en) | 2015-08-28 | 2021-10-19 | Uwm Research Foundation, Inc. | HDAC inhibitors and methods of treatment using the same |
US12054711B2 (en) | 2017-07-14 | 2024-08-06 | City Of Hope | Meta-stable oligonucleotides junctions for delivery of therapeutics |
EP3665281A4 (en) * | 2017-08-10 | 2021-05-05 | City of Hope | CONDITIONAL-siRNAS AND USES THEREOF IN TREATING CARDIAC HYPERTROPHY |
WO2019235501A1 (en) * | 2018-06-06 | 2019-12-12 | 塩野義製薬株式会社 | Histone deacetylase inhibitor |
CN113166750A (en) | 2018-08-10 | 2021-07-23 | 希望之城 | Programmable conditional SIRNA and uses thereof |
JP7522726B2 (en) | 2019-03-28 | 2024-07-25 | 株式会社カネカ | Method for producing pyrrole-imidazole (poly)amide |
CN110951738B (en) * | 2019-12-23 | 2021-10-15 | 华南农业大学 | Expression inhibitor of pig HDAC2 gene and application thereof |
CN112062826A (en) * | 2020-06-01 | 2020-12-11 | 暨南大学 | Acetylation modified H2B protein marker molecule related to central nervous senescence and application thereof |
CN116270932B (en) * | 2021-12-13 | 2024-08-23 | 南京大学 | Angong bezoar bolus small RNA combination for treating brain injury diseases and application thereof |
CN115192714B (en) * | 2022-07-08 | 2024-09-17 | 沈阳药科大学 | Use of HDAC6 inhibitors in the manufacture of a medicament for the treatment of DNMT3A gene-deficient cancers |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040077591A1 (en) * | 2002-03-28 | 2004-04-22 | The Brigham And Women's Hospital, Inc. | Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease |
WO2006052916A2 (en) * | 2004-11-08 | 2006-05-18 | Errant Gene Therapeutics, Inc. | Histone deacetylase inhibitors |
US20070078083A1 (en) * | 2005-09-07 | 2007-04-05 | Braincells, Inc. | MODULATION OF NEUORGENESIS BY HDac INHIBITION |
US20080057529A1 (en) * | 2003-12-18 | 2008-03-06 | Michele Pallaoro | Method for Identifying Histone Deacetylase Inhibitors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050054647A1 (en) * | 2002-12-27 | 2005-03-10 | Detlev Schuppan | New pharmaceutical combination |
TW200424174A (en) * | 2003-02-06 | 2004-11-16 | Hoffmann La Roche | New TP diamide |
US20060018921A1 (en) * | 2004-07-16 | 2006-01-26 | Baylor College Of Medicine | Histone deacetylase inhibitors and cognitive applications |
JP2008540574A (en) * | 2005-05-11 | 2008-11-20 | タケダ サン ディエゴ インコーポレイテッド | Histone deacetylase inhibitor |
WO2008086452A2 (en) * | 2007-01-10 | 2008-07-17 | Columbia University | Treatment and prevention of alzheimer's disease |
-
2009
- 2009-12-02 JP JP2011539506A patent/JP2012510512A/en active Pending
- 2009-12-02 US US13/132,179 patent/US20120101147A1/en not_active Abandoned
- 2009-12-02 WO PCT/US2009/006355 patent/WO2010065117A1/en active Application Filing
- 2009-12-02 EP EP09830725A patent/EP2367599A4/en not_active Withdrawn
- 2009-12-02 NZ NZ593447A patent/NZ593447A/en not_active IP Right Cessation
- 2009-12-02 AU AU2009322958A patent/AU2009322958B2/en not_active Ceased
- 2009-12-02 CN CN2009801532239A patent/CN102271763A/en active Pending
- 2009-12-02 CA CA2745073A patent/CA2745073A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040077591A1 (en) * | 2002-03-28 | 2004-04-22 | The Brigham And Women's Hospital, Inc. | Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease |
US20080057529A1 (en) * | 2003-12-18 | 2008-03-06 | Michele Pallaoro | Method for Identifying Histone Deacetylase Inhibitors |
WO2006052916A2 (en) * | 2004-11-08 | 2006-05-18 | Errant Gene Therapeutics, Inc. | Histone deacetylase inhibitors |
US20070078083A1 (en) * | 2005-09-07 | 2007-04-05 | Braincells, Inc. | MODULATION OF NEUORGENESIS BY HDac INHIBITION |
Non-Patent Citations (1)
Title |
---|
See also references of EP2367599A4 * |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8841346B2 (en) | 2009-10-30 | 2014-09-23 | Massachusetts Institute Of Technology | Use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders |
EP2493298A1 (en) * | 2009-10-30 | 2012-09-05 | Massachusetts Institute of Technology | The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders |
EP2493298A4 (en) * | 2009-10-30 | 2013-04-10 | Massachusetts Inst Technology | The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders |
US8563615B2 (en) | 2009-10-30 | 2013-10-22 | Massachusetts Institute Of Technology | Use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders |
EP2598133A2 (en) * | 2010-07-30 | 2013-06-05 | The Regents of The University of California | Method and therapeutic for the treatment and regulation of memory formation |
EP2598133A4 (en) * | 2010-07-30 | 2014-03-05 | Univ California | Method and therapeutic for the treatment and regulation of memory formation |
CN102477001A (en) * | 2010-11-29 | 2012-05-30 | 江苏先声药物研究有限公司 | Benzamide histone deacetylase inhibitor |
CN102477001B (en) * | 2010-11-29 | 2015-07-15 | 江苏先声药物研究有限公司 | Benzamide histone deacetylase inhibitor |
US9447030B2 (en) | 2011-04-28 | 2016-09-20 | Massachusetts Institute Of Technology | Inhibitors of histone deacetylase |
US11572368B2 (en) | 2011-04-28 | 2023-02-07 | The General Hospital Corporation | Inhibitors of histone deacetylase |
JP2014523857A (en) * | 2011-04-28 | 2014-09-18 | ザ ブロード インスティテュート, インコーポレイテッド | Histone deacetylase inhibitor |
US9365498B2 (en) | 2011-04-28 | 2016-06-14 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
US10662199B2 (en) | 2011-04-28 | 2020-05-26 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
US9890172B2 (en) | 2011-04-28 | 2018-02-13 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
US10167277B2 (en) | 2011-07-22 | 2019-01-01 | Massachusetts Institute Of Technology | Activators of class I histone deacetlyases (HDACs) and uses thereof |
US9115053B2 (en) | 2011-07-22 | 2015-08-25 | Massachusetts Institute Of Technology | Activators of class I histone deacetlyases (HDACS) and uses thereof |
US11084803B2 (en) | 2011-07-22 | 2021-08-10 | Massachusetts Institute Of Technology | Activators of class I histone deacetylases (HDACs) and uses thereof |
WO2013017542A1 (en) * | 2011-07-29 | 2013-02-07 | Georg-August-Universität Göttingen | Method for preventing or treating memory impairment and pharmaceutical compositions useful therefor |
AU2018203354B2 (en) * | 2011-12-21 | 2019-12-05 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US9790184B2 (en) | 2012-07-27 | 2017-10-17 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
US11377423B2 (en) | 2012-07-27 | 2022-07-05 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
US9914717B2 (en) | 2012-12-20 | 2018-03-13 | The Broad Institute, Inc. | Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors |
US10793538B2 (en) | 2012-12-20 | 2020-10-06 | The Broad Institute, Inc. | Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors |
EP2801569A1 (en) | 2013-05-09 | 2014-11-12 | Ikerchem, S.L. | Histone deacetylase inhibitors based on derivatives of tricyclic polyhydroacridine and analogs possessing fused saturated five- and seven-membered rings |
WO2014180984A1 (en) | 2013-05-09 | 2014-11-13 | Ikerchem, S.L. | Histone deacetylase inhibitors based on derivatives of tricyclic polyhydroacridine and analogs possessing fused saturated five- and seven-membered rings |
WO2019014418A1 (en) * | 2017-07-13 | 2019-01-17 | Massachusetts Institute Of Technology | Targeting the hdac2-sp3 complex to enhance synaptic function |
EP3982968A4 (en) * | 2019-06-13 | 2023-07-05 | Dana-Farber Cancer Institute, Inc. | Hdac3 catalytic inhibitor development and uses thereof |
WO2021117759A1 (en) | 2019-12-10 | 2021-06-17 | 塩野義製薬株式会社 | Histone deacetylase inhibitor having nitrogen-containing aromatic heterocyclic group |
US12043607B2 (en) | 2021-12-03 | 2024-07-23 | Tango Therapeutics, Inc. | HDAC inhibitors and therapeutic use thereof |
Also Published As
Publication number | Publication date |
---|---|
US20120101147A1 (en) | 2012-04-26 |
EP2367599A4 (en) | 2012-08-08 |
EP2367599A1 (en) | 2011-09-28 |
JP2012510512A (en) | 2012-05-10 |
AU2009322958A1 (en) | 2011-07-07 |
CA2745073A1 (en) | 2010-06-10 |
CN102271763A (en) | 2011-12-07 |
AU2009322958B2 (en) | 2015-03-19 |
NZ593447A (en) | 2012-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2009322958B2 (en) | Inhibition of HDAC2 to promote memory | |
US8088951B2 (en) | Epigenetic mechanisms re-establish access to long-term memory after neuronal loss | |
US10881656B2 (en) | HIF inhibitors and use thereof | |
Bunney et al. | Rapid-acting antidepressant strategies: mechanisms of action | |
ES2908863T3 (en) | Pharmaceutical composition for the treatment of autism | |
Chaudhury et al. | The role and therapeutic potential of Hsp90, Hsp70, and smaller heat shock proteins in peripheral and central neuropathies | |
US20080188524A1 (en) | Methods of treating pain | |
KR20150009540A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
IL268125B2 (en) | Use of pridopidine for the treatment of fragile x syndrome | |
JP2009534415A (en) | Pharmacological control of the action of AMPA receptor modulators on neurotrophin expression | |
KR20110070919A (en) | Synergistic combination of sphingosine-1-phosphate receptor antagonists and antimicrotubule agents | |
JP2021001221A (en) | Iloperidone metabolite for use in treatment of psychiatric disorders | |
BR112019028034A2 (en) | nk-1 antagonist compositions and methods for use in the treatment of depression | |
Kameyama et al. | Possible contribution of the sarcoplasmic reticulum Ca2+ pump function to electrical and mechanical alternans | |
ES2358931T3 (en) | USE OF A P38 QUINASE INHIBITOR FOR THE TREATMENT OF PSYCHIATRIC DISORDERS. | |
US20170119760A1 (en) | Use of masitinib for the treatment of progressive supranuclear palsy | |
JP2018522936A (en) | MDM2 inhibitors for the treatment of uveolar melanoma | |
CN110290788A (en) | Carbamate compounds are used to prevent, alleviate or treat the purposes of bipolar disorders | |
JP2004503497A (en) | Analgesic and anti-inflammatory compositions containing COX-2 inhibitors | |
CN109715149A (en) | The method for treating oophoroma | |
AU2010256541B2 (en) | Modulation of KCNQ potassium channel activity for treatment of psychiatric disorders and the symptoms thereof | |
KR20230058615A (en) | Drugs for the treatment of motor complications of Parkinson's disease | |
US20170105952A1 (en) | Histone acetyl transferase activators and histone deacetylase inhibitors in the treatment of alcoholism | |
KR20200099153A (en) | Treatment of post-traumatic syndrome disorder | |
JP2022138903A (en) | Anti-depression or anti-anxiety agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980153223.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09830725 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2745073 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011539506 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4258/DELNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009322958 Country of ref document: AU Ref document number: 593447 Country of ref document: NZ |
|
REEP | Request for entry into the european phase |
Ref document number: 2009830725 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009830725 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2009322958 Country of ref document: AU Date of ref document: 20091202 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13132179 Country of ref document: US |